| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b updated data readout example | Iopofosine I 131 Multiple B‑cell malignancies including multiple myeloma, non-Hodgkin's lymphoma, and Waldenström macroglobulinemia (pivotal expansion cohort) | Phase 2b | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | |
Phase 2b updated data readout example | Iopofosine I 131 Multiple B‑cell malignancies including multiple myeloma, non-Hodgkin's lymphoma, and Waldenström macroglobulinemia (pivotal expansion cohort) | Phase 2b | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | |
Phase 2b updated data readout example | Iopofosine I 131 Multiple B‑cell malignancies including multiple myeloma, non-Hodgkin's lymphoma, and Waldenström macroglobulinemia (pivotal expansion cohort) | Phase 2b | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology |
Recent Updates
Recently added Catalysts
Cellectar Biosciences, Inc.$2.82
-0.06 (-2.09%)
C 46Pipeline Score Fair Value Pharma · Clinical
Market Cap
25.57 M
EPS
-7.37
P/E Ratio
-
Value Trade
640.99 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.01 M
Operating CF
-4.85 M
Total Assets
11.12 M
Total Liabilities
6.40 M
Equity
3.34 M
D/E Ratio
12,345
-1.84 %
Week
14.29 %
1 Month
-5.33 %
3 Month
7.38 %
6 Month
-99.26 %
5 Year
-100 %
All Time
Cash Data
Cash Position
8.35 M
Monthly Burn
1.61 M
Runway
3.5 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
68.27 K
52 Week Range
2.43 - 20.59
% held by Insiders
2.07 %
% held by Institutions
19.67 %
Enterprise Value
20.66 M
Total Shares
7.99 M
Short %
0.73 %
Float Shares
7.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cellectar Biosciences, Inc.
801Total events
7Upcoming
148Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 7
TBD
T2Trial Initiation
Planned initiation of Phase 1b clinical study of CLR 125 in triple-negative breast cancer
Event history 794
Q3 2026
◆EU MAA SubmissionEx-US Regulatory
Submit for conditional marketing approval in Europe
Waldenstrom's Macroglobulinemiasource ↗
Jun 1, 2026
◆Poster PresentationPresentation
Poster presentation of CLOVER-WaM subgroup efficacy and safety data at ASCO 2026
Waldenström macroglobulinemiasource ↗
Jun 2026
◆Interim AnalysisTrial
Interim data from Phase 1b study of CLR 125 for TNBC
Triple Negative Breast Cancersource ↗
Jun 2026
◆Topline ReadoutClinical Data
Early data from Phase 1b CLR 125 study expected by mid-year 2026
Triple Negative Breast Cancersource ↗
May 14, 2026
May 14, 2026
▲Full ResultsClinical Data
Positive 12-month follow-on data for Iopofosine I 131 in r/r WM
relapsed/refractory Waldenström Macroglobulinemiasource ↗
May 14, 2026
▲Trial InitiationTrial
Dosed first patients in Phase 1b dose finding study for CLR 125 in TNBC
Triple Negative Breast Cancersource ↗
Apr 14, 2026
▲First Patient DosedTrial
First patient enrolled in Phase 1b trial of CLR 125 for TNBC
refractory triple negative breast cancersource ↗
Q2 2026
◆Enrollment UpdateTrial
Additional study sites being activated in Q2 2026
refractory triple negative breast cancersource ↗
Q2 2026
◆Timing GuidancePresentation
Early dosimetry, safety and efficacy data expected mid-year 2026
Triple Negative Breast Cancersource ↗
Drug Pipeline Intelligence
C46
Pipeline Score $23M
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored0.9x
rNPV / MCap Top 68%
Micro Cap (rank 293 of 911)
Percentile RankCellectar Biosciences, Inc. carries a moderate pipeline score (46/100), with $2.3B risk-adjusted pipeline value, led by Iopofosine I 131 single dose in Waldenstrom Macroglobulinemia (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iopofosine I 131 single dose Small molecule | Waldenstrom Macroglobulinemia | Phase 2 | NCT02952508 | 57% | $946M | ACTIVE NOT_RECRUITING | 120 | AVERAGE | C (40) | Dec 22, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
iopofosine I 131 BreakthroughFast TrackAccelerated+2 | relapsed or refractory pediatric high-grade glioma | Phase 1b | 2025-10-27 | PFS: 5.4 months; OS: 8.6 months; n: 6; additional dosing PFS: 8.1 months; additional dosing OS: 11.5 months; additional dosing range: 4.9 to 14.9 months; objective response: 2 Read More | Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma Read More | |
iopofosine I 131 BreakthroughFast TrackAccelerated+2 | relapsed or refractory pediatric high-grade glioma | Phase 1b | 2025-10-27 | PFS: 5.4 months; OS: 8.6 months; n: 6; additional dosing PFS: 8.1 months; additional dosing OS: 11.5 months; additional dosing range: 4.9 to 14.9 months; objective response: 2 Read More | Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma Read More | |
iopofosine I 131 BreakthroughFast TrackAccelerated+2 | relapsed or refractory pediatric high-grade glioma | Phase 1b | 2025-10-27 | PFS: 5.4 months; OS: 8.6 months; n: 6; additional dosing PFS: 8.1 months; additional dosing OS: 11.5 months; additional dosing range: 4.9 to 14.9 months; objective response: 2 Read More | Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLRB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLRB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLRB▼ -5.4%on this news
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Cellectar Biosciences announced promising efficacy data from its Phase 2 CLOVER WaM study of iopofosine I 131 for treating relapsed or refractory Waldenström macroglobulinemia. The study reported a major response rate of 79.2% and a median duration of response of 16 months. The company plans to initiate a Phase 3 confirmatory trial in Q4 2026, aiming for accelerated approval in the U.S.
Read more →CLRB▲ +8.8%on this news
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenstr m Macroglobulinemia (r/r
Cellectar Biosciences has reported its financial results for the first quarter of 2026, highlighting significant progress in its clinical pipeline. The company secured up to $140 million in financing to support advancements in their lead compound, iopofosine I 131, for the treatment of relapsed/refractory Waldenström macroglobulinemia. Recent follow-up data from the CLOVER-WaM study indicated promising efficacy and will support a Phase 3 study. Additionally, Cellectar has initiated a Phase 1b trial for CLR 125 in triple-negative breast cancer, emphasizing their commitment to developing innovative cancer therapies.
Read more →CLRBCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Cellectar Biosciences will report its first quarter financial results on May 14, 2026, at 8:30 a.m. ET. The company focuses on developing cancer treatments using its proprietary Phospholipid Drug Conjugate platform. Its lead product, iopofosine I 131, has received several FDA designations and is currently in various clinical trials. CLR 125 is also being evaluated for solid tumors, showing promising preclinical data.
Read more →CLRB▲ +12.4%on this news
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Cellectar Biosciences announced an oversubscribed financing round totaling up to $140 million, aimed at supporting a confirmatory study and NDA filing for its drug, Iopofosine I 131, targeting Waldenström macroglobulinemia. The financing was led by Nantahala Capital Management with backing from other notable institutional investors and will enhance Cellectar's ability to advance its proprietary drug conjugate delivery platform. Following the financing close, Andrew Gu from Nantahala will join the company’s Board of Directors. The initiative underscores investor confidence in Cellectar's treatment options for unmet medical needs in oncology.
Read more →CLRBCellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Cellectar Biosciences announced that an abstract detailing subset data from their CLOVER WaM clinical trial has been accepted for presentation at the American Society of Clinical Oncology Annual Meeting in June 2026. This data focuses on the treatment of relapsed or refractory Waldenström's Macroglobulinemia (WM) patients, highlighting the significant unmet medical need in this population. The company emphasizes the encouraging safety and efficacy results for its investigational drug, iopofosine I-131, which may provide new therapeutic options for patients who have already progressed on BTK inhibitors.
Read more →CLRB▲ +7.7%on this news
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Cellectar Biosciences announced the enrollment of the first patient in a Phase 1b clinical trial for CLR 125, a radioconjugate aimed at treating refractory triple negative breast cancer (TNBC). CLR 125 utilizes an Auger-emitting platform to deliver targeted cytotoxic radiation to tumor cells. Initial preclinical studies suggest that CLR 125 has effective tumor-targeting characteristics and minimal systemic toxicity. The trial aims to assess safety, tolerability, and preliminary efficacy across different dosing regimens.
Read more →CLRB▲ +8.2%on this news
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Cellectar Biosciences reported its financial results for 2025, highlighting significant progress in its clinical pipeline. The company is preparing to submit a Conditional Marketing Authorization for iopofosine I-131 in Europe and has initiated a Phase 1b study for CLR 125 in Triple Negative Breast Cancer. Despite a net loss of $21.8 million, Cellectar remains optimistic about its future prospects and ongoing clinical developments.
Read more →CLRBCellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Cellectar Biosciences, Inc. will report its full year financial results for 2025 and provide a corporate update on March 4, 2026. The company focuses on developing cancer treatments using its proprietary Phospholipid Drug Conjugate delivery platform. Its lead product, iopofosine I 131, has received several FDA designations, highlighting its potential in treating various cancers.
Read more →CLRB▼ -5.2%on this news
Cellectar Biosciences Expands Global Intellectual Property Estate
Cellectar Biosciences has expanded its global intellectual property estate, securing new patents across multiple regions. This expansion enhances protection for its cancer-targeting drug, iopofosine I 131, as the company prepares for a conditional marketing approval filing with the EMA for Waldenström macroglobulinemia. The CEO highlighted the importance of this development for their long-term strategy and commitment to improving treatment options for patients.
Read more →CLRB▼ -6.9%on this news
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Cellectar Biosciences will present its strategic initiatives for 2026 at the Biotech Showcase during the JP Morgan Healthcare Conference. The company aims to submit for conditional marketing approval of iopofosine I 131 for Waldenstrom’s Macroglobulinemia in Europe by Q3 2026. Additionally, they plan to initiate a Phase 1b study for CLR 125 targeting triple negative breast cancer in early 2026.
Read more →CLRBCellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Cellectar Biosciences has entered a multi-year supply agreement with Ionetix for Actinium-225 and Astatine-211, essential radioisotopes for advancing its targeted alpha therapy programs. This partnership aims to support Cellectar in clinical trials and potential commercial launches of its therapies for solid tumors like pancreatic cancer. Ionetix is enhancing its production capabilities with additional cyclotrons to meet the growing demand for these isotopes. The collaboration is poised to strengthen Cellectar's ability to deliver innovative cancer treatments.
Read more →CLRB▼ -18%on this news
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cellectar Biosciences reported its third quarter 2025 financial results, highlighting significant advancements in its drug development pipeline. The company expects to submit a conditional marketing approval application for iopofosine I 131 in Europe in 2026 and has initiated a Phase 1b study for CLR 125. Additionally, iopofosine I 131 has received multiple FDA designations, reinforcing its potential in treating various cancers.
Read more →CLRBCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Cellectar Biosciences, Inc. will report its financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025. The company specializes in developing drugs for cancer treatment using its proprietary Phospholipid Drug Conjugate delivery platform. Their lead asset, iopofosine I 131, has received several designations from the FDA aimed at accelerating its development for various cancer indications.
Read more →CLRB▼ -10.3%on this news
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
Cellectar Biosciences has received Rare Pediatric Disease Designation from the FDA for iopofosine I 131, aimed at treating relapsed or refractory pediatric high-grade glioma. The designation highlights the drug's potential to address a severe pediatric cancer. Interim results from the CLOVER-2 trial indicate significant improvements in progression-free and overall survival among patients. The company is optimistic about further development and collaboration opportunities.
Read more →CLRBCellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Cellectar Biosciences presented promising preclinical data for CLR 225 at the AACR Special Conference. The data highlighted CLR 225's effectiveness in targeting pancreatic ductal adenocarcinoma, showcasing its anti-tumor activity and safety profile. The findings support advancing CLR 225 into Phase 1 studies, aiming to improve treatment outcomes for pancreatic cancer patients.
Read more →CLRB▼ -16.9%on this news
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
Cellectar Biosciences, Inc. has entered agreements with institutional investors to raise approximately $5.8 million by exercising existing warrants. The funds will be utilized for working capital, a Phase 1b clinical study of CLR 121125 in triple-negative breast cancer, and preparing for a Conditional Marketing Authorization with the EMA. The company continues to advance its innovative cancer treatment pipeline.
Read more →CLRB▲ +6.7%on this news· ran to -17% by day 3shared move
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
Cellectar Biosciences announced that the EMA has confirmed the eligibility for filing a Conditional Marketing Authorization (CMA) for iopofosine I 131 as a treatment for refractory Waldenstrom macroglobulinemia. The company plans to submit the CMA application in early 2026, with a potential European approval and commercial launch expected in 2027. Iopofosine I 131 has shown promising clinical results and has received PRIME designation from the EMA.
Read more →CLRBCellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Cellectar Biosciences presented interim data from its Phase 1b study of iopofosine I 131 at the AACR Special Conference on Pediatric Cancer. The data showed promising results in treating relapsed or refractory pediatric high-grade gliomas, with significant tumor volume reduction and extended survival rates. The treatment was well tolerated, with manageable adverse effects.
Read more →CLRB▲ +11.2%on this news
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
Cellectar Biosciences has partnered with Evestia Clinical to conduct a Phase 1b trial for CLR 125, targeting triple-negative breast cancer (TNBC). The collaboration leverages Evestia's oncology expertise and resources following its merger with Atlantic Research Group. The trial will take place at a Mayo Clinic site, ensuring experienced clinical oversight.
Read more →CLRB▲ +5.6%on this news
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Cellectar Biosciences has entered a supply agreement with ITM for Actinium-225 to support the clinical development of its cancer treatment candidate, CLR 121225. This compound is designed to target solid tumors, including pancreatic cancer. The agreement aims to ensure a reliable supply of the isotope, crucial for advancing Cellectar's therapeutic pipeline.
Read more →CLRB▲ +5.2%on this newsshared move
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Cellectar Biosciences is set to participate in the Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit. The company is optimistic about its discussions with the EMA regarding a potential conditional marketing authorization for Iopofosine I 131 for Waldenstrom Macroglobulinemia. Additionally, Cellectar plans to pursue accelerated FDA approval for the same drug and is advancing its CLR 125 candidate into a Phase 1b trial for triple-negative breast cancer.
Read more →CLRBCellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
Cellectar Biosciences, Inc. has announced that its COO, Jarrod Longcor, will speak at several medical meetings and conferences in September 2025. Topics will include advancements in targeted radiopharmaceuticals and innovative approaches to pediatric cancer treatment. Cellectar emphasizes its commitment to developing proprietary cancer therapies using its Phospholipid Drug Conjugate delivery platform. The company has received numerous FDA designations for its lead asset, iopofosine I 131, underlining its therapeutic promise.
Read more →CLRBCellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
Cellectar Biosciences, Inc. announced the acceptance of a poster abstract for presentation at the AACR Special Conference on Pancreatic Cancer Research. The poster will feature preclinical data on CLR 121225, a novel actinium-based radio conjugate targeting hypoxic pancreatic ductal adenocarcinoma. The company has reported promising results regarding activity, biodistribution, and uptake in animal models and is advancing regulatory activities towards IND submission. The conference is scheduled to take place from September 28 to October 1 in Boston, Massachusetts.
Read more →CLRBCellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Cellectar Biosciences announced that an abstract has been accepted for oral presentation at the AACR Special Conference focusing on pediatric cancer. The presentation will feature interim data from the Phase 1b CLOVER-2 trial, which assesses iopofosine I 131 in treating pediatric high-grade gliomas. This trial involves patients with aggressive brain tumors and aims to optimize both dose and regimen of the treatment. The company expresses optimism regarding the findings and their potential impact on treatment options for patients with this challenging condition.
Read more →CLRBCellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treat
Cellectar Biosciences reported its second quarter 2025 financial results and provided a corporate update on its drug development efforts. The company plans to submit an NDA for accelerated approval of iopofosine I-131 to the FDA for treating Waldenstrom Macroglobulinemia, contingent on funding requirements. Cellectar is also working towards initiating a confirmatory trial and advancing CLR 125 into clinical trials for triple-negative breast cancer. The company remains in discussions with potential partners to facilitate the NDA filing and commercialization efforts.
Read more →CLRBCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
Cellectar Biosciences, a late-stage clinical biopharmaceutical company, will report its financial results for the second quarter ending June 30, 2025, on August 14, 2025, at 8:30 a.m. ET. The announcement highlights Cellectar’s commitment to developing proprietary cancer treatments through its Phospholipid Drug Conjugate platform. Noteworthy is the status of its lead product, iopofosine I 131, which has received multiple FDA designations that enhance its market potential. The company intends to provide a corporate update during the conference call alongside the financial results.
Read more →CLRBCellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Cellectar Biosciences announced the successful closing of a $6.9 million underwritten public offering aimed at funding its corporate purposes and a Phase 1b clinical trial for CLR 121125 in triple-negative breast cancer. The offering was supported by healthcare dedicated funds and included the full exercise of an over-allotment option. With the securities sold under an SEC registration statement, the gross proceeds signal strong market confidence in Cellectar's potential developments in cancer therapies.
Read more →CLRB▼ -31.6%on this newsshared move
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
Cellectar Biosciences has announced the pricing of an underwritten public offering, expected to generate approximately $6 million in gross proceeds. The offering includes Class A Units and Class B Units, and the funds raised will be allocated for general corporate purposes, including a Phase 1b clinical study of CLR 121125 for treating triple-negative breast cancer. The offering is set to close around July 2, 2025, pending customary conditions.
Read more →CLRB▼ -7.1%on this news· ran to -39% by day 3shared move
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Cellectar Biosciences has entered into a multi-year supply agreement with Nusano for iodine-125 and actinium-225. This partnership supports Cellectar's clinical studies, particularly the planned Phase 1b trial of CLR-125 for treating triple-negative breast cancer. The agreement ensures a stable supply of these critical isotopes, enabling the advancement of Cellectar's targeted radiotherapy pipeline. Nusano aims to enhance the production capabilities of medical radioisotopes, addressing market demands.
Read more →CLRB▲ +8.6%on this newsshared move
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Cellectar Biosciences announced the submission of a Phase 1b clinical trial protocol to the FDA for CLR 125, a radiopharmaceutical aimed at treating triple-negative breast cancer (TNBC). The study will investigate the safety and effectiveness of three different dosing regimens in 15 patients per arm, while leveraging imaging techniques to assess tumor uptake. This initiative builds on positive preclinical results and highlights the urgent need for innovative treatment options in a challenging disease landscape.
Read more →CLRBCellectar Biosciences Announces One-for-Thirty Reverse Stock Split
Cellectar Biosciences has announced a one-for-thirty reverse stock split effective June 24, 2025. This decision was approved by stockholders to reduce the total number of shares and potentially enhance the stock's market value. The reverse stock split will not alter stockholders' ownership percentages but will result in cash payments for any fractional shares. This change also affects the company's equity incentive plans and outstanding stock options.
Read more →CLRB▲ +16.6%on this news
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
Cellectar Biosciences has announced positive initial results from its CLOVER-2 Phase 1 clinical trial involving iopofosine I 131 for pediatric patients with relapsed/refractory high-grade gliomas. Patients receiving the drug showed average progression-free survival (PFS) of 5.4 months and overall survival (OS) of 8.6 months. Notably, those who received additional dosing demonstrated even better outcomes. The early findings suggest encouraging evidence of clinical efficacy for this treatment in a difficult-to-treat patient demographic.
Read more →CLRB▼ -11.6%on this news· ran to -22% by day 1
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Cellectar Biosciences has entered into agreements to raise $2.5 million through the sale of common stock priced at-market under Nasdaq rules. The funding is expected to close around June 6, 2025, pending customary conditions. The net proceeds from this offering will be used for general corporate purposes, including working capital. Cellectar is known for its cancer treatment development, leveraging its proprietary Phospholipid Drug Conjugate delivery platform, which aims to improve safety and efficacy in therapeutic applications.
Read more →CLRB▲ +66.3%on this newsshared move
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Cellectar Biosciences, Inc. announced that the FDA has granted Breakthrough Therapy Designation for its drug iopofosine I 131, aimed at treating relapsed/refractory Waldenstrom macroglobulinemia. This designation is supported by promising data from the Phase 2 CLOVER WaM study, which showed an 83.6% overall response rate. The company is also seeking guidance from the EMA regarding potential fast-track marketing authorization. The situation indicates strong potential for iopofosine I 131 in improving treatment options for patients with this life-threatening cancer.
Read more →CLRB▼ -9.1%on this news
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobul
Cellectar Biosciences has reported its financial results for the first quarter of 2025 and announced its intention to seek conditional marketing approval for Iopofosine I 131 from the European Medicines Agency. The company highlighted positive findings from the Phase 2 CLOVER study, showing noteworthy response rates among BTK-treated patients. Despite a reported net loss and decreased cash reserves, Cellectar remains focused on advancing its pipeline of radiotherapeutics. A conference call detailing the financial results is scheduled for today, accompanied by a corporate update on its ongoing projects.
Read more →CLRBCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Cellectar Biosciences, Inc. announced it will report its first quarter financial results and provide a corporate update on May 13, 2025. The company is focused on developing drugs for cancer treatment, leveraging its proprietary Phospholipid Drug Conjugate delivery platform. Its product pipeline includes several promising candidates for difficult-to-treat cancers, and the company holds various regulatory designations that may facilitate its drug's path to market. A replay of the conference call will be available on its Investor Relations website afterwards.
Read more →CLRB▼ -13.5%on this news
Cellectar Announces Plan to Explore Strategic Alternatives Florham Park, N.J.
Cellectar Biosciences, Inc. announced plans to explore strategic alternatives to enhance stockholder value, including potential mergers and partnerships. The company's board has engaged Oppenheimer & Co. Inc. as its financial advisor to assist in this evaluation process. Although this move reflects a proactive approach to advancing their drug development pipeline, no specific transaction agreements have been reached, and there’s no assurance that any agreement will be completed. Cellectar’s focus remains on its innovative cancer treatment candidates, including iopofosine I 131.
Read more →CLRB▼ -5.4%on this news· ran to +19% by day 3
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of
Cellectar Biosciences reported its financial results for the year ending December 31, 2024, along with a corporate update. Key highlights include achieving alignment with the FDA on the regulatory path for the accelerated approval of iopofosine I 131 for treating Waldenström macroglobulinemia. The company plans to advance additional radioconjugates into Phase 1 clinical studies, while also navigating significant operational losses due to increased expenses. The ongoing developments and potential collaborations position Cellectar strategically for future growth.
Read more →CLRBCellectar Biosciences to Present at the 37th Annual Roth Conference
Cellectar Biosciences, Inc. has announced that its management team will present at the 37th Annual Roth Conference on March 17, 2025. The presentation will provide an overview of the company's ongoing development and commercialization of cancer treatments, leveraging their proprietary Phospholipid Drug Conjugate platform. Cellectar's product pipeline includes promising assets with FDA designations, underscoring their potential in addressing significant unmet needs in cancer care.
Read more →CLRB▲ +6.6%on this news
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
Cellectar Biosciences, Inc. has announced that it will report its full-year financial results for December 31, 2024, on March 13, 2025. The company aims to provide a corporate update during a conference call scheduled for that date at 8:30 a.m. Eastern Time. Cellectar is focused on developing targeted cancer treatments using its proprietary Phospholipid Drug Conjugate delivery platform, with several candidates in its product pipeline receiving favorable designations from the FDA.
Read more →CLRBCellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Cellectar Biosciences, Inc. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. The presentation will provide an overview of the company's developments and its proprietary Phospholipid Drug Conjugate delivery platform for cancer treatments. Cellectar's pipeline includes several promising assets, including iopofosine I 131, which has received multiple FDA designations, indicating its potential in treating various cancers.
Read more →CLRBCellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR
Cellectar Biosciences plans to present its 2025 strategic initiatives at the upcoming Biotech Showcase during the JP Morgan Healthcare Conference. The company showcased positive results from the Phase 2 CLOVER-WaM study for Iopofosine I 131, achieving an 83.6% overall response rate. Cellectar aims for accelerated approval pathways in the U.S. and EU, intending to enhance its pipeline with new radiotherapeutic agents and promising cancer treatments. The presentation will be delivered by CEO James Caruso on January 14, 2025.
Read more →CLRB▼ -5.2%on this news· ran to -81% by day 3
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Cellectar Biosciences announced a strategic update focusing on its clinical pipeline and corporate restructuring. The company is exploring options for the commercialization of its lead drug candidate, iopofosine I 131, which has shown promising results for treating Waldenstrom's macroglobulinemia. Cellectar also plans to advance two other radiotherapeutic programs into Phase 1 solid tumor studies while undergoing a significant workforce reduction. This restructuring aims to extend the company’s operational runway and concentrate on the most promising therapeutic candidates in its portfolio.
Read more →CLRBCellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66 th Annual American Society of Hematology Meeting and
Cellectar Biosciences announced its Q3 2024 financial results and a corporate update, highlighting key achievements including the funding raised and developments in its pivotal CLOVER-WaM study. The company aims to submit a New Drug Application (NDA) for accelerated approval following positive study results. However, the company also reported a significant net loss for the quarter, alongside rising operating expenses, underscoring the challenges it faces in the current market environment.
Read more →CLRBCellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Cellectar Biosciences has entered into a strategic supply agreement with NorthStar Medical Radioisotopes to secure non-carrier-added Actinium-225 (Ac-225) for clinical programs. This partnership is pivotal for Cellectar's CLR 121225 development program which aims to treat solid tumors and is set to advance to human trials in 2025. The ongoing shortage of Ac-225 has been a challenge for many in the field, but this agreement with NorthStar is expected to facilitate Cellectar's drug development efforts.
Read more →CLRBCellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar Biosciences has entered into a partnership with SpectronRx to manufacture its first-in-class cancer therapy, iopofosine I 131. This collaboration aims to enhance the supply chain for advanced cancer treatments, particularly for Waldenstrom's macroglobulinemia. Iopofosine I 131 has demonstrated efficacy in clinical trials and is planned for a New Drug Application submission soon. SpectronRx will utilize its facilities in Indiana and Belgium for the production of this investigational drug, which has received Orphan Drug and Fast Track designations from the FDA.
Read more →CLRBCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Cellectar Biosciences, Inc. has announced plans to report its third quarter financial results for the period ending September 30, 2024, and provide a corporate update on November 18, 2024. The conference call will take place at 8:30 a.m. Eastern Time, and a replay will be available on their investor relations website. Cellectar focuses on developing innovative cancer treatments using its proprietary Phospholipid Drug Conjugate delivery platform.
Read more →CLRBCellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Cellectar Biosciences, Inc. announced that new data from its Phase 2 CLOVER-WaM study of iopofosine I 131, a treatment for Waldenstrom's macroglobulinemia, will be presented at the 2024 ASH Annual Meeting. The data are anticipated to highlight the drug's efficacy and safety in treating patients with relapsed/refractory disease. Cellectar aims to submit a New Drug Application to the FDA soon, seeking priority review due to the lack of effective therapies currently available for these patients. The presence of iopofosine I 131 represents a potential breakthrough in treatment options for this patient population.
Read more →CLRBCellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Cellectar Biosciences announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the submission of restated financial statements. These filings included comprehensive financial data for previous fiscal years and quarterly periods. The company's ongoing focus on developing targeted cancer treatments through its proprietary drug delivery platform highlights its commitment to innovation in the biopharmaceutical field. This news is seen as a positive step for Cellectar as it continues to advance its pipeline of cancer therapies.
Read more →CLRBCellectar to Restate Previously Issued Financial Statements - Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
Cellectar Biosciences, Inc. announced it received a delinquency notification from Nasdaq for failing to comply with filing requirements regarding its Quarterly Report on Form 10-Q. The delay stems from the company's need to restate previously issued financial statements due to a reassessment of its accounting treatment for warrants. Cellectar has a 60-day timeframe to present a compliance plan to Nasdaq, with a possible extension if the plan is accepted. The company aims to complete the restatement process within six weeks.
Read more →CLRB▲ +8.6%on this news
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update Management to host a conference call today at 8:30 am
Cellectar Biosciences (NASDAQ: CLRB) has reported its financial results for Q2 2024 and provided a corporate update, highlighting a positive data announcement from the CLOVER WaM pivotal study. The company is focused on filing a New Drug Application (NDA) for its lead asset, iopofosine I 131, in Waldenstrom's macroglobulinemia within the fourth quarter of 2024. Cellectar anticipates an expedited review process and aims for a potential market launch in 2025. Additionally, management will conduct a conference call to discuss these developments in detail.
Read more →CLRBCellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
Cellectar Biosciences, Inc. is set to announce its first quarter financial results for the period ending June 30, 2024, on August 13, 2024. A conference call will commence at 8:30 AM Eastern Time, where management will discuss the financial results and provide updates. Cellectar is focused on developing drugs for cancer treatment, leveraging its proprietary Phospholipid Drug Conjugate™ platform. This announcement marks a crucial step for the company as it continues to advance its pipeline of targeted therapies.
Read more →CLRB▼ -18.5%on this news
Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months 80% Overall Response Rate Achi
Cellectar Biosciences announced that its investigational drug, Iopofosine I 131, has exceeded key endpoints in the CLOVER WaM study for treating relapsed/refractory Waldenstrom's Macroglobulinemia. The study demonstrated an overall response rate of 80% and a major response rate of 56.4%, with 78% of patients progression-free at 18 months. The drug was well tolerated, with a favorable safety profile compared to existing therapies. Cellectar aims to submit a New Drug Application (NDA) by Q4 2024, seeking priority review from the FDA.
Read more →CLRB▲ +19.8%on this newsshared move
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
Cellectar Biosciences has announced the exercise of Tranche B warrants, generating approximately $19.4 million. Investors also purchased new warrants that may raise an additional $73.3 million. The funds will facilitate the company's commercialization processes, particularly for their lead asset, iopofosine I 131. The company is preparing to file a New Drug Application for this treatment by the end of 2024. These financial activities reflect bullish investor sentiment regarding Cellectar's prospects in the oncology sector.
Read more →CLRB▼ -19.4%on this news
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will host a key opinion leader (KOL) event on July 24, 2024, to review results from its pivotal CLOVER WaM trial for iopofosine I 131 in treating Waldenstrom’s macroglobulinemia. The meeting will feature discussions from company leadership and leading investigators on trial outcomes and market needs. There are no current FDA-approved treatment options available for patients who have progressed on BTKi therapies, highlighting the necessity for new therapeutic approaches.
Read more →CLRBCellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences has entered into a strategic partnership with City of Hope Cancer Center to assess the efficacy of its lead radioconjugate asset, iopofosine I 131, in treating mycosis fungoides, a rare form of non-Hodgkin's lymphoma. The upcoming clinical trial aims to enroll about 10 patients, anticipating initiation in late 2024. This collaboration is anticipated to explore the potential of iopofosine, which is already recognized for its benefits in treating indolent non-Hodgkin's lymphoma and may address significant unmet needs in this patient population. The partnership enhances Cellectar's position in the oncology sector, particularly given City of Hope's expertise in cancer research and treatment.
Read more →CLRBCellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June
Cellectar Biosciences reported its financial results for Q1 2024, highlighting a net loss of $21.6 million, reflecting an increase from the previous year. The company has announced plans to release data from its CLOVER WaM pivotal study in June and aims to submit its New Drug Application (NDA) later in 2024. Positive developments include favorable patient enrollment in their pediatric glioma study and ongoing exploration of their cancer-targeting drug delivery platform. However, rising costs and financial losses pose challenges for the company.
Read more →CLRBCellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
Cellectar Biosciences, a late-stage clinical biopharmaceutical company, will be presenting at the Guggenheim Healthcare Talks Radiopharmaceuticals Day on May 13, 2024. The session will feature the company’s COO, Jarrod Longcor, discussing its focus on cancer treatment through its proprietary drug delivery platform. Cellectar's product pipeline includes the lead asset iopofosine I 131 and several ongoing partnerships aimed at enhancing cancer treatment efficacy and safety.
Read more →CLRBCellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
Cellectar Biosciences, Inc. is set to announce its financial results for Q1 2024 on May 14, 2024. The company, specializing in cancer treatment drug development, will also conduct a conference call to discuss these results in detail. This event represents an opportunity for investors to gain insights into the company's progress, including developments in their proprietary drug delivery platform and product pipeline. The call is scheduled for 8:30 AM Eastern Time and will be accessible via toll-free numbers and webcast.
Read more →CLRB▼ -5.6%on this news
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update Management to host a conference call today at 8:30 am
Cellectar Biosciences has announced its financial results for the year ending December 31, 2023, reporting notable progress in its clinical development, particularly regarding its lead asset, iopofosine I 131, which has shown promising data in treating Waldenstrom's macroglobulinemia. The company plans to file its New Drug Application (NDA) in the latter half of 2024, potentially seeking accelerated approval. Despite positive progress, Cellectar faces challenges with considerable losses and current liabilities surpassing total assets, highlighting some financial strain.
Read more →CLRBCellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Cellectar Biosciences, Inc. announced that it will report its financial results for the year ending December 31, 2023, on March 27, 2024. The company will host a conference call at 8:30 am Eastern Time to discuss these results and provide an overview. Cellectar is focused on developing drugs for cancer treatment, leveraging its Phospholipid Drug Conjugate delivery platform. Important details for accessing the conference call have been provided to investors, signifying the company's commitment to communication.
Read more →CLRBCellectar Biosciences to Present at the 36th Annual Roth Conference
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has announced that Jim Caruso, the company’s president and CEO, will present at the 36th Annual Roth Conference scheduled for March 17 to 19, 2024, in Laguna Niguel, CA. The presentation will cover an overview of the company's initiatives, including its proprietary Phospholipid Drug Conjugate™ delivery platform aimed at enhancing cancer treatment effectiveness and safety. This event will provide a platform for Cellectar to engage with potential investors and share insights about its product pipeline, notably the lead asset, iopofosine I 131.
Read more →CLRBCellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Cellectar Biosciences reported positive outcomes from an investigator-initiated Phase I study of iopofosine I 131 combined with external beam radiotherapy in recurrent head and neck cancer patients. The study highlighted a significant complete remission rate of 64% and an overall survival rate of 67% after one year. Despite some adverse events noted in 92% of participants, the combination therapy demonstrated favorable safety and durability of response, suggesting potential for broader application in solid tumors. The findings were presented at the Multidisciplinary Head and Neck Cancers Symposium.
Read more →CLRBCellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Cellectar Biosciences, Inc. announced that CEO James Caruso will present an overview of the company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The presentation will highlight the company's late-stage clinical development of cancer drugs, including their proprietary Phospholipid Drug Conjugate delivery platform. A replay of the presentation will be available on the company's investor relations website following the event. Cellectar aims to improve cancer treatment outcomes through targeted therapies.
Read more →CLRB▼ -5.7%on this news
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Cellectar Biosciences has announced the enrollment of the first patient in its Phase 1b clinical trial for iopofosine I 131, targeting pediatric patients with relapsed or refractory malignant high-grade gliomas. This innovative phospholipid radiotherapeutic conjugate has shown promising results in earlier studies, including the ability to cross the blood-brain barrier. The trial is backed by a $2 million grant from the National Cancer Institute and aims to evaluate the drug's safety, tolerability, and optimal dosing. There is a significant need for effective treatments in this challenging area of pediatric oncology, as current options are limited.
Read more →CLRB▲ +6.8%on this news· ran to +18% by day 3shared move
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Cellectar Biosciences has announced the full exercise of Tranche A warrants from a previous private placement, generating approximately $44.1 million in proceeds. This funding will support the company’s lead asset, iopofosine I 131, as it prepares for a New Drug Application submission and potential FDA approval. Cellectar is also continuing its clinical development for various cancers with significant unmet needs. The development comes amid previously issued Tranche B warrants that could yield additional funding in the future.
Read more →CLRBCellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
Cellectar Biosciences has reported the successful complete clearance of central nervous system (CNS) malignancy in a patient with relapsed/refractory Waldenstrom's macroglobulinemia, who was treated with their drug iopofosine I 131 during the Phase 2b CLOVER WaM pivotal trial. The achievement indicates a significant therapeutic advance for patients suffering from CNS involvement, presenting a potential new option for those with limited treatments available. The promising results could pave the way for further exploration of iopofosine in other CNS-related malignancies.
Read more →CLRB▲ +5.4%on this news
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Cellectar Biosciences announced positive preclinical results for its alpha-emitting phospholipid radiotherapeutic conjugate, CLR 121225, targeting pancreatic cancer. The compound showed significant anti-tumor effects in mouse models, with high doses leading to nearly complete tumor eradication. The company plans to initiate IND-enabling studies for a Phase I clinical trial of CLR 121225, while also expanding its pipeline to include targeted alpha therapies. Cellectar's unique PLE delivery platform is expected to enhance treatment efficacy for solid tumors.
Read more →CLRBCellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
Cellectar Biosciences, Inc. has announced a conference call scheduled for January 19, 2024, to discuss the positive topline results of iopofosine I 131, a treatment for relapsed/refractory Waldenstrom’s macroglobulinemia. The call will feature Dr. M. Yair Levy, a hematologist from Texas Oncology, providing his insights into the study results. The company's approach utilizes their proprietary Phospholipid Drug Conjugate™ platform to enhance the efficacy and safety of cancer treatments.
Read more →CLRBCellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Cellectar Biosciences has entered into a partnership with the American Oncology Network and its subsidiary MiBA to improve the treatment of Waldenstrom's macroglobulinemia (WM) in the community setting. With promising topline data from the CLOVER WaM study showing a 61% major response rate for iopofosine I 131, this collaboration aims to ensure patient access to cutting-edge radiotherapies. The partnership also focuses on understanding provider and patient needs to enhance upcoming FDA approval strategies. AON's extensive network of clinics will play a pivotal role in this initiative, catering to a significant number of WM patients across the U.S.
Read more →CLRB▲ +18.1%on this news· ran to +35% by day 1shared move
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia Iopofosine tested in heavily pretreated multi-class refrac
Cellectar Biosciences has reported positive topline data from its CLOVER WaM pivotal study, demonstrating that its Iopofosine I 131 treatment achieved notable efficacy in heavily pretreated patients with Waldenstrom's macroglobulinemia. The study had a 75.6% overall response rate and a 61% major response rate, with all patients experiencing disease control. Additionally, the treatment's safety profile was consistent with previous reports, showing no treatment-related deaths. Cellectar plans to submit these results in their NDA application, seeking accelerated approval based on the promising outcomes.
Read more →CLRBCellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
Cellectar Biosciences will provide top-line data from its pivotal trial of iopofosine I 131 in Waldenstrom's macroglobulinemia on January 8, 2024. This announcement is part of a call to detail the results to investors. Following the call, the company will also present at the Biotech Showcase conference. Cellectar aims to leverage its proprietary drug delivery platform to develop targeted cancer treatments.
Read more →CLRBCellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Cellectar Biosciences has announced a new exclusive licensing agreement with the Wisconsin Alumni Research Foundation to develop iopofosine I 131 for various pediatric solid cancers. This collaboration builds on prior research from the University of Wisconsin-Madison and strengthens Cellectar's patent portfolio related to iopofosine. Additionally, the company has received a $2 million grant from the NCI to further study iopofosine's efficacy in treating pediatric high-grade gliomas. Cellectar continues to focus on delivering targeted cancer treatments through its proprietary drug development platform.
Read more →CLRBCellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Cellectar Biosciences, Inc. has strengthened its intellectual property by securing patent allowances for its Phospholipid Drug Conjugate platform in several key countries, including Japan and China. The patents protect both the composition and usage of its targeted cancer therapies involving flavaglines. The company is preparing to report pivotal data for its lead therapy, iopofosine I 131, in January 2024, while also aiming to diversify its product offerings for high-need cancers. However, the path of drug development remains fraught with challenges, including financial and regulatory uncertainties.
Read more →CLRBCellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
Cellectar Biosciences announced that COO Jarrod Longcor will present and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe in Berlin from December 5-7, 2023. The presentation will focus on advancements in targeted radiotherapies, including the use of alpha and beta particles for treating malignancies. This summit will bring together innovators in the field to explore the challenges and successes of radiopharmaceuticals, highlighting Cellectar's proprietary PLE delivery platform as a potential universal targeting agent in cancer treatment.
Read more →CLRBCellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of
Cellectar Biosciences, Inc. announced that it will release top-line data from its pivotal trial in Waldenstrom's macroglobulinemia during the JP Morgan Healthcare Conference in January 2024. The company sees this data announcement as a potentially pivotal moment that warrants increased market awareness. Additionally, with a recent funding round of up to $102.9 million, Cellectar is well-positioned to advance its lead asset, iopofosine I 131. Management will hold a conference call to discuss the company's financial results and updates on November 2, 2023.
Read more →CLRBCellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Cellectar Biosciences has partnered with Florida Cancer Specialists & Research Institute to improve treatments for Waldenstrom's macroglobulinemia within the community oncology setting. The collaboration seeks to address unmet needs in the treatment landscape while evaluating iopofosine I 131, which has received Fast Track Designation from the FDA. As part of their initial strategy, Cellectar aims to undertake several community-based collaborations to enhance patient access and clinical success. The company also anticipates releasing pivotal trial data later this year, with a potential 2024 product launch in view.
Read more →CLRBCellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will announce its financial results for the third quarter of 2023 on November 2, 2023, and host a conference call with investors at 8:30 am ET. The call will discuss their performance and provide insights into the Waldenstrom’s macroglobulinemia market and their lead product, iopofosine I 131. Cellectar focuses on developing targeted cancer treatments using its proprietary Phospholipid Drug Conjugate™ delivery platform and aims to minimize off-target effects.
Read more →CLRBCellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
Cellectar Biosciences announced key appointments in its commercialization leadership team, positioning itself for an expected pivotal data release for iopofosine I-131 in Waldenstrom's macroglobulinemia. William Yoon and Aaditya Nanduri join as vice presidents, bringing extensive experience in medical affairs and business strategy. The company is preparing for a potential NDA filing and a planned product launch in 2024. These developments come as the market for targeted treatments in WM remains undersupplied.
Read more →CLRB▲ +8.3%on this news
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
Cellectar Biosciences, Inc. announced the expansion of its global intellectual property portfolio with the granting of four patents in key regions, including Europe, Australia, and Canada. These patents pertain to their proprietary Phospholipid Drug Conjugate™ delivery platform and their lead drug iopofosine I 131, which focuses on treating various cancers, including gliomas and melanoma. The enhancements in IP protection are expected to support future clinical advancements and reinforce the company's mission to transform cancer care. CEO James Caruso emphasized the importance of safeguarding intellectual assets for the benefit of cancer patients worldwide.
Read more →CLRBCellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
Cellectar Biosciences has been awarded the European Medicines Agency's PRIME designation for its lead drug candidate, iopofosine I 131, aimed at treating Waldenstrom's macroglobulinemia. This designation signals a potential major therapeutic advantage and aims to accelerate regulatory processes for medicines addressing unmet medical needs. The company anticipates submitting a new drug application (NDA) in March 2024, following the release of pivotal trial data in late 2023. Additionally, iopofosine has already received Fast Track Designation from the FDA for similar patient groups in the U.S.
Read more →CLRBCellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
Cellectar Biosciences, Inc. has completed a private placement financing that could raise up to approximately $103 million, which includes $24.5 million received at closing. The financing was led by Rosalind Advisors and includes the issuance of Series E-1 Preferred Stock and warrants. Cellectar's lead asset, iopofosine, has received Fast Track Designation from the FDA, with the company targeting a potential product launch in 2024 following pivotal trial data release later this year. However, risks related to shareholder dilution and uncertainties in clinical development remain.
Read more →CLRB▲ +36.3%on this news
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
Cellectar Biosciences has secured up to $103 million through a private placement financing led by Rosalind Advisors. This funding is intended to fully finance corporate activities, including pivotal trials for its lead asset, iopofosine, with top-line data expected in Q4 2023. The financing is structured to provide capital necessary for the potential accelerated approval and commercialization of the drug in the near future. The agreement also includes various warrants and preferred stock issuances, reflecting investor confidence in the company's pipeline.
Read more →CLRBCellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
Cellectar Biosciences, Inc. announced its financial results for Q2 2023 and provided a corporate update. The company is focused on developing its investigational drug, iopofosine I 131, which aims to address a need in relapsed or refractory Waldenström’s Macroglobulinemia. Cellectar continues to build its proprietary Phospholipid Drug Conjugate delivery platform, which is designed to improve cancer treatment efficacy and safety. While the company is optimistic about the future, it faces risks including substantial financial losses and potential supply chain issues.
Read more →CLRBCellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
Cellectar Biosciences presented interim data from an ongoing study of iopofosine I 131 in 64 refractory multiple myeloma patients at the SNMMI Annual Meeting. The results revealed an overall response rate of 28%, notably higher among highly refractory subgroups, with a disease control rate of 92%. Adverse events primarily included cytopenias, but no off-target effects were reported, bolstering the treatment's profile. The company is expected to provide further data in their Phase 2 CLOVER-1 study and aims for a product launch in late 2024.
Read more →CLRBCellectar Provides a Research and Development Program Summary Waldenstrom's macroglobulinemia pivotal trial topline data now expected second half of 2023; pediatric high grade glioma trial to initiate in Q3 Phospholipid
Cellectar Biosciences has updated its research and development program, specifically focusing on its iopofosine I 131 clinical program for Waldenstrom's macroglobulinemia. The company anticipates releasing top-line data from its pivotal trial in the second half of 2023 and aiming for a product launch in 2024, following site activations that have improved patient enrollment. Additionally, with support from a National Cancer Institute grant, Cellectar plans to initiate a Phase 1b trial for pediatric high-grade gliomas in Q3 2023, highlighting the potential of its phospholipid drug conjugate platform.
Read more →CLRBCellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
Cellectar Biosciences, Inc. announced its financial results for the first quarter of 2023, highlighting significant operational momentum in its pivotal trial of iopofosine for Waldenstrom's macroglobulinemia. The company expressed optimism about the year ahead, anticipating key data announcements from multiple clinical trials. Financially, Cellectar reported a net loss of $8.58 million, reflecting increased expenses. However, they continue to prepare for the commercial launch of iopofosine and advancements in other key programs.
Read more →CLRB▼ -10.5%on this news
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
Cellectar Biosciences, Inc. announced its financial results for the year ending December 31, 2022, showcasing significant corporate developments. The company has 43 global sites actively recruiting for its pivotal study in Waldenstrom's macroglobulinemia and achieved encouraging response rates in ongoing trials. Additionally, leadership has been bolstered with key hires to support its commercial strategy. However, financial losses and uncertainties pose challenges as the company aims for continued advancement in targeted cancer therapies.
Read more →CLRBCellectar to Participate at Upcoming Banking Conferences
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced its upcoming participation in the Roth Capital Partners 35th Annual Conference on March 13, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. At these events, the company will be available for 1x1 meetings with investors. Cellectar continues to focus on the development of its cancer-targeting drugs, particularly its iopofosine PDC program, which is under investigation in various clinical trials. The company's proprietary technology aims to improve drug efficacy while minimizing side effects.
Read more →CLRBCellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
Cellectar Biosciences announced a complete response in a patient with relapsed/refractory primary central nervous system lymphoma enrolled in its Phase 2 CLOVER-1 Trial. The 61-year-old female had previously undergone extensive treatment with limited success. After receiving iopofosine I 131, a CT scan showed complete resolution of the tumor, indicating the drug's potential in treating challenging CNS lymphomas. This case emphasizes iopofosine's ability to effectively target CNS cancers where few treatment options exist.
Read more →CLRBCellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
Cellectar Biosciences has appointed Dr. Andrei Shustov as Senior Vice President, Medical, to enhance its clinical and medical affairs. Dr. Shustov brings over 30 years of experience in hematology and has previously worked at Seagen, Inc. He is expected to lead the development of iopofosine and other pipeline assets. The company is actively pursuing approvals for iopofosine in several cancer indications, including Waldenstrom’s macroglobulinemia.
Read more →CLRBCellectar Biosciences Announces Shane Lea as Chief Commercial Officer
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of S
Read more →CLRBCellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
FLORHAM PARK, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the presentation of
Read more →CLRBCellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
FLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that Cellectar Biosciences, Inc.
Read more →CLRB▼ -6.9%on this news
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update PARK, N.J., November 3, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted
Read more →CLRBCellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has closed o
Read more →CLRB▼ -7.1%on this newsshared move
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
FLORHAM PARK, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered
Read more →CLRB▼ -9%on this news
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors September 22, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercializa
Read more →CLRBCellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature's Blood Cancer Journal Initial data show ORR of 50% in Q
Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature's Blood Cancer Journal data show ORR of 50% in Quad-Class Refractory Multiple Myeloma Patients Who Have Failed anti-BCMA Imm
Read more →CLRBCellectar Reports Financial Results for Second Quarter 2022
Cellectar Reports Financial Results for Second Quarter 2022 PARK, N.J., August 5, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today ann
Read more →CLRB▲ +5.4%on this news· ran to -23% by day 3
Cellectar Announces Stock Consolidation
FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that, as authorized by its stock
Read more →CLRB▲ +5.4%on this news· ran to -23% by day 3
Cellectar Announces Stock Consolidation Florham Park, N.J.
Cellectar Announces Stock Consolidation Florham Park, N.J., July 21, 2022 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that, a
Read more →CLRB▼ -8.1%on this news
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update PARK, N.J., May 10, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of tar
Read more →CLRB▼ -6.3%on this news
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom's Macroglobulinemia Unanimous Agreement on Successful Achievement of Futility/Efficacy Assessment
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom's Macroglobulinemia Unanimous Agreement on Successful Achievement of Futility/Efficacy Assessment PARK, N.J., April 26, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a la
Read more →CLRBCellectar Biosciences Announces Key Commercial Team Appointments
Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances David Lasecki Appointed Executive Director, Strategic Alliances FLORHAM PARK, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical c
Read more →CLRB▲ +15.8%on this news
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update March 21, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targete
Read more →CLRBCorporate Presentation March 2022 N A S D A Q : C L RB Forward - Looking Statements 2 This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to
Corporate Presentation March 2022 N A S D A Q : C L RB Forward - Looking Statements 2 This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update this information . These statements are only estima
Read more →CLRBCellectar Biosciences Announces Executive Leadership Changes Names Mr. Chad Kolean as Chief Financial Officer Promotes Mr. Jarrod Longcor to Chief Operating Officer FLORHAM PARK, N.J., February 23 , 2022 -- Cellectar Bio
Cellectar Biosciences Announces Executive Leadership Changes Names Mr. Chad Kolean as Chief Financial Officer Longcor to Chief Operating Officer PARK, N.J., February 23, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focu
Read more →CLRBCellectar Biosciences Announces Executive Leadership Changes
Names Mr. Chad Kolean as Chief Financial Officer Promotes Mr. Jarrod Longcor to Chief Operating Officer FLORHAM PARK, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, de
Read more →CLRBCellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced Jim Caruso,
Read more →CLRBCellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma Mean ORR of 45.5%, CBR of 72.7% and DCR of 100% and the subset of quad/penta drug refractory patients had an ORR of 80% and CBR of 100% FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE NEWSW
Read more →CLRBCellectar Biosciences Announces Poster Presentation at the 63 rd American Society for Hematology Annual Meeting and Exposition FLORHAM PARK, N.J., December 8 , 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-s
Cellectar Biosciences Announces Poster Presentation at the Society for Hematology Annual Meeting and Exposition PARK, N.J., December 8, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development an
Read more →CLRBCellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster pr
Read more →CLRBCellectar's Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors FLORHAM PARK, N.J., November 16 , 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical
Cellectar's Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors PARK, N.J., November 16, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development a
Read more →CLRBCellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update PARK, N.J., November 8, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs
Read more →CLRBCellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer Successful track record of developing and advancing oncology clinical programs through regulatory approval
Laurence Reilly, M.D., LL.M Interim Chief Medical Officer Successful track record of developing and advancing oncology clinical programs through regulatory approval November 2, 2021 - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company f
Read more →CLRBCellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies Company to provide patient support and services; partners with BBK Worldwide FLORHAM PARK, N.J., October 25 , 2021 -- Ce
Innovative Concierge Service for Patients Participating in Its Clinical Studies patient support and services; partners with BBK Worldwide PARK, N.J., October 25, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the
Read more →CLRBPreliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer Initiation of Expansion Cohort of Up to 24 Patients FLORH
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Initiation of Expansion Cohort of Up to 24 Patients PARK, N.J., September 22, 2021 -- Cellectar Biosciences, Inc. (NASDA
Read more →CLRBCellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit PARK, N.J., September 15, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the tr
Read more →CLRBCellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia August 18, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and de
Read more →CLRBCellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 13
Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131) Agreement adds second manufacturer and expands Cellectar's curr
Read more →CLRBCellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate PARK, N.J., August 9, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatme
Read more →CLRBCellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc. Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)
Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc. Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs) PARK, N.J., July 13, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharm
Read more →CLRBCellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs) Development of Multiple Novel PDCs
Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Development of Multiple PARK, N.J., July 12, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on
Read more →CLRBCellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference July 8, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, toda
Read more →CLRBCellectar Announces the Election of Dr. Asher Alban Chanan-Khan to its Board of Directors
Cellectar Announces the Election of Dr. Asher to its Board of Directors June 24, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced t
Read more →CLRBCellectar Presents Data in Waldenstrom's Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Mean treatment free remission 1.1 years and remains ongoing Progression free su
Data in Waldenstrom's Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting remission 1.1 years and remains ongoing Progression free survival for MYD88 wild type and high-risk patients 18 months and ongoing PARK, N.J., June 4, 2
Read more →CLRBCellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom's Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Management to host a KOL call with Dr. Sikandar Ailawadhi
Poster Presentation of CLR 131 Data in Waldenstrom's Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator May 20, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biop
Read more →CLRBCellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 May 14, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, t
Read more →CLRBCellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM) Received European Orphan Drug Designation for CLR
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM) Received European Orphan Drug Designation for Strong cash position of approximately $54 million providing cash
Read more →CLRBCellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico New patent covers phospholipid-ether analogs combined with various small molecule c
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs PARK, N.J., Apr.
Read more →CLRBCellectar to Participate at Upcoming Institutional Investor Conferences
Participate at Upcoming Institutional Investor Conferences N.J., March 11, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, toda
Read more →CLRBCellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates Covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs
Cellectar Granted Japanese Composition for its Phospholipid-Ether Drug Conjugates Covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs N.J., March 9, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-sta
Read more →CLRBCellectar Reports Financial Results for Year Ended
Financial Results for Year Ended December 31, 2020 N.J., March 2, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announce
Read more →CLRBCellectar to Present at BIO CEO & Investor Digital Conference FLORHAM PARK, N.J., February 10 , 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery
Present at BIO CEO & Investor Digital Conference N.J., February 10, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today annou
Read more →CLRBCellectar to Present at BIO CEO & Investor Digital Conference
FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso,
Read more →CLRBCellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia Benefits include 10 years of market exclusivity in the European Union FLORHAM PARK, N.J., January 27
Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia include 10 years of market exclusivity in the European Union N.J., January 27, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company
Read more →CLRBCellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom's Macroglobulinemia FLORHAM PARK, N.J., January 12 , 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused
Cellectar Initiates Pivotal Trial of in Waldenstrom's Macroglobulinemia FLORHAM PARK, N.J., January 12, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs fo
Read more →CLRBCellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its p
Read more →CLRBCellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
Cellectar Biosciences Announces Pricing of $24.5 Million Public Offering and $20.5 Million Concurrent Private Placement N.J., December 23, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development
Read more →CLRBCorporate Presentation December 2020 NASDAQ: CLRB Forward - Looking Statements 2 This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to upda
Corporate Presentation December 2020 NASDAQ: CLRB Forward - Looking Statements 2 This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update this information . These statements are only estimates a
Read more →CLRBCellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement
FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it intends to o
Read more →CLRBCellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Third Quarter 2020 Financial Results N.J., November 9, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial
Read more →CLRBCellectar Biosciences' CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors CLR 131 crosses blood brain barrier delivering drug directly to brain tumors FLORHAM PARK, N.J., Nove
Cellectar Biosciences' CLR 131 Demonstrates Preliminary Activity for Pediatric Brain and Solid Tumors blood brain barrier delivering drug directly to brain tumors PARK, N.J., November 5, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutic
Read more →CLRBCellectar Biosciences to Present at Two Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president
Read more →CLRBCellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients 40% overall response rate (ORR) with a total administered dose of 60 mCi or greater
Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients 40% overall response rate (ORR) with a total administered dose of 60 mCi or greater FLORHAM PARK, N.J., September 9, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLR
Read more →CLRBCellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (
Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) show 100% overall response rate and a 75% major response rate N.J., Au
Read more →CLRBCellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
Second Quarter 2020 Financial Results N.J., August 10, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial resu
Read more →CLRBCellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting Data highlight results from the Phase 1 study of CLR 131 in children and adolescents with relapsed
Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting results from the Phase 1 study of CLR 131 in children and adolescents with relapsed/refractory malignancies N.J., August 4, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB),
Read more →CLRBCellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Rel
Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom's Macroglobulinemi
Read more →CLRBCellectar Appoints Dr. John Friend as Chief Medical Officer
Dr. John Friend as Chief Medical Officer N.J., July 1, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has ap
Read more →CLRBCellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various sm
be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics FLORHAM PARK, N.J., June 11, 2020 -- Cellectar Biosciences
Read more →CLRBCellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
Cellectar Biosciences Announces Closing Underwritten Public Offering FLORHAM PARK, N.J., June 5, 2020 - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of c
Read more →CLRBCellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
Cellectar Biosciences Announces Pricing Underwritten Public Offering FLORHAM PARK, N.J., June 3, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatme
Read more →CLRBCellectar Granted SME Status by the European Medicines Agency Designation Comes with Financial and Scientific Incentives
SME Status by the European Medicines Agency Comes with Financial and Scientific Incentives FLORHAM PARK, N.J., June 1, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
Read more →CLRBCellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Waldenstrom's Macroglobulinemia FLORHAM PARK, N.J., May 26, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and
Read more →CLRBCellectar Granted Composition of Matter and Use Patent in Europe for CLR 131 Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125
Composition of Matter and Use Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125 N.J., May 14, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and comme
Read more →CLRBCellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update
First Quarter 2020 Financial Results N.J., May 7, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results f
Read more →CLRBClinical Data Call
Clinical Data Call February 19, 2020 This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update this information . These statements are only estimates and predictions and are subject to known and
Read more →CLRBCellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in relapsed/refractory B-cell Lymphomas and Completion of the Phase 1 relapsed/refractory Multiple Myeloma Dose
Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in relapsed/refractory B-cell Lymphomas and Completion of the Phase 1 relapsed/refractory Multiple Myeloma Dose Escalation Study 42.8% ORR in multiple myeloma at the 75
Read more →CLRBCellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020 FLORHAM PARK, N.J., January 09, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, developme
Read more →CLRBCellectar Appoints Dr. Igor Grachev as Chief Medical Officer
FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor
Read more →CLRBE xhibit 99.1 Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
Appoints Dr. Igor Grachev as Chief Medical Officer PARK, N.J., January 7, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today annou
Read more →CLRBCellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)
Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL) FLORHAM PARK, N.J., January 6, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the tr
Read more →CLRBCellectar Biosciences to Present at Biotech Showcase 2020
Cellectar Biosciences to Present at Biotech Showcase 2020 N.J., December 19, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today a
Read more →CLRBCellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of CLR 131 anticipated in January FLORHAM PARK, N.J., Dec. 16, 2019 (GLOBE NEWSWI
Read more →CLRBCellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium Efficacy established in 4 th class of molecules utilizing Phospholipid Ether Vehicle
Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium Efficacy established in 4th class of molecules utilizing Phospholipid Ether Vehicle N.J., December 13, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biophar
Read more →CLRBFractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61 st Annual American Society of Hematology Conference 50% overall response rate in cohort of patients receiving fr
Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference N.J., December 9, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the dis
Read more →CLRBCellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at t
Read more →CLRBCellectar Announces Oral Presentation at the 61 st Annual American Society of Hematology Conference
Oral Presentation at the 61st Annual American Society of Hematology Conference N.J., December 2, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment
Read more →CLRBCellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
Third Quarter 2019 Financial Results and Provides a Corporate Update N.J., November 12, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cance
Read more →CLRBCellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference Data demonstrating in vivo efficacy and tolerability with a novel PDC, CLR 180099
Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in vivo efficacy and tolerability with a novel PDC, CLR 180099 N.J., October 30, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage
Read more →CLRBCellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston N.J., October 17, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs
Read more →CLRBCellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors
Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology phospholipid ether (PLE) molecules ability to target wide range of tumors N.J., October 15, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceut
Read more →CLRBCellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology N.J., October 8, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat
Read more →CLRBCellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress Data showed durable clinical responses, including a 33% overall response rate (ORR) and
Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR) N.J., September 30, 2019 -- Cellectar Biosciences, Inc. (NA
Read more →CLRBCellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma
Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma FLORHAM PARK, N.J., September 24, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
Read more →CLRBCellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
FLORHAM PARK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president
Read more →CLRBCellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma Data presented at the 17th International Myeloma Workshop Patients in Cohort 6 achieved a meanin
Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma at the 17th International Myeloma Workshop Cohort 6 achieved a meaningful clinical benefit with a 50% overall response rate and 100% disease control N.J., September 16, 201
Read more →CLRBCellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019 Data from an interim evaluation of CLR 131 in relapsed or refractory DLBCL patients will be presented
Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019 interim evaluation of CLR 131 in relapsed or refractory DLBCL patients will be presented N.J., September 10, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutica
Read more →CLRBCellectar Announces Late-Breaker Poster Presentation at the 17 th International Myeloma Workshop
Late-Breaker Poster Presentation at the 17th International Myeloma Workshop N.J., September 4, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment o
Read more →CLRBCellectar Appoints Dov Elefant as Chief Financial Officer Seasoned executive with over two decades of corporate finance and operational leadership experience in the biopharmaceuticals industry to join Cellectar team
Dov Elefant as Chief Financial Officer with over two decades of corporate finance and operational leadership experience in the biopharmaceuticals industry to join Cellectar N.J., Aug. 15, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical com
Read more →CLRBCLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study Independent Data Monitoring Committee recommends the study continue to higher dose after first dose deemed safe and tolerated
to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study Data Monitoring Committee recommends the study continue to higher dose after first dose deemed safe and tolerated N.J., Aug. 14, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopha
Read more →CLRBCellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
Second Quarter 2019 Financial Results and Provides a Corporate Update N.J., August 12, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer
Read more →CLRBCellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma N.J., July 9, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer,
Read more →CLRBCellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131 Response rate exceeded pre-specified value; top-line results of Phase 2 study expected in 2019
Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131 exceeded pre-specified value; top-line results of Phase 2 study expected in 2019 FLORHAM PARK, N.J., May 21, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on
Read more →CLRBCellectar Biosciences Announces Closing of $10.0 Million Financing
Cellectar Biosciences Announces Closing of $10.0 Million Financing FLORHAM PARK, N.J., May 20, 2019 (GLOBE NEWSWIRE) - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs f
Read more →CLRBCellectar Biosciences Announces $10.0 Million Financing
Cellectar Biosciences Announces $10.0 FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, to
Read more →CLRBCLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease contr
50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Data Monitoring Committee determines dose to be safe and well tole
Read more →CLRBCellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma Designation could accelerate CLR 131 development and underscores the need for new treatments
Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma Designation could accelerate CLR 131 development and underscores the need for new treatments N.J., May 13, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharma
Read more →CLRBCellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Anno
First Quarter 2019 Financial Results and Provides a Corporate Update top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131
Read more →CLRBFDA Grants Exemption to Import Alert for Cellectar's CLR 131 in Pediatric and Adolescent Patients Company to initiate Phase 1 study in pediatric and adolescent patients with select relapsed or refractory solid tumors, ly
Grants Exemption to Import Alert for Cellectar's CLR 131 in Pediatric and Adolescent Patients Phase 1 study in pediatric and adolescent patients with select relapsed or refractory solid tumors, lymphomas and malignant brain N.J., Mar. 19, 2019 -- Cellectar Biosciences, Inc. (N
Read more →CLRBCellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131 Company's lead product candidate previously demonstrated positive top-line results from the di
Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131 lead product candidate previously demonstrated positive top-line results from the diffuse large B-cell lymphoma cohort of this tumor types is ongoing; Cellectar intends t
Read more →CLRBCellectar Biosciences to Present at the Annual BIO CEO & Investor Conference
FLORHAM PARK, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, presid
Read more →CLRBCorporate Presentation January 2019 NASDAQ: CLRB Forward - Looking Statements This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update
Corporate Presentation January 2019 NASDAQ: CLRB Forward - Looking Statements This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update this information . These statements are only estimates and
Read more →CLRBCellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference
FLORHAM PARK, N.J., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, preside
Read more →CLRBCellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma Median overall survival of 22.0 months observed in Cohorts 1-4 FLORHAM PARK, N.J. (
Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma Median overall survival of 22.0 months observed in Cohorts 1-4 FLORHAM PARK, N.J. (January 7, 2019) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical compan
Read more →CLRBCellectar Biosciences to Present at the Biotech Showcase
FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that James Caruso, president and c
Read more →CLRBCellectar Granted Japanese Patent for CLR 131 Patent covers composition of matter and use in solid and liquid tumor cancer indications FLORHAM PARK, N.J. (
Cellectar Granted Japanese Patent for Patent covers composition of matter and in solid and liquid tumor cancer indications FLORHAM PARK, N.J. (December 11, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery,
Read more →CLRBCellectar Granted Japanese Patent for CLR 131
FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the Japan Patent Office has g
Read more →CLRBCellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma Patient enrolled at highest fractionated two-dose regimen to date FLORHAM PARK, N.J. (
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma Patient enrolled at highest fractionated two-dose regimen to date FLORHAM PARK, N.J. (December 4, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharm
Read more →CLRBCellectar Reports Third Quarter 2018 Financial Results and Provides Business Update FLORHAM PARK, N.J. (
Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update FLORHAM PARK, N.J. (November 13, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or "the Company"), a clinical-stage biopharmaceutical company focused on the discovery, develop
Read more →CLRBCellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J. (
Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies Clinical Trials to Advance Across Multiple FLORHAM PARK, N.J. (November 12, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the di
Read more →CLRBCellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma MADISON, Wis. (
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma MADISON, Wis. (October 2, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, developm
Read more →CLRBCorporate Presentation October 2018 NASDAQ: CLRB Forward - Looking Statements This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update
Corporate Presentation October 2018 NASDAQ: CLRB Forward - Looking Statements This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update this information . These statements are only estimates and
Read more →CLRBCellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference
MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president
Read more →CLRBCellectar's CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma Madison, Wis.
Cellectar's CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma Madison, Wis., September 25, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerciali
Read more →CLRBCellectar Biosciences Provides an Update on the FDA Import Alert
Cellectar Biosciences Provides an Update on the FDA Import Alert MADISON, Wis., September 24, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment o
Read more →CLRBFDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Osteosarcoma Madison, Wis.
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Osteosarcoma Madison, Wis., September 17, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development an
Read more →CLRBCorporate Presentation September 2018 NASDAQ: CLRB Forward - Looking Statements This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to updat
Corporate Presentation September 2018 NASDAQ: CLRB Forward - Looking Statements This presentation contains forward - looking statements . Such statements are valid only as of today and we disclaim any obligation to update this information . These statements are only estimates an
Read more →CLRBCellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president a
Read more →CLRBFractionated Dosing Improves Tolerability and Safety of Cellectar's CLR 131 in R/R Multiple Myeloma Patients Positive Results from Cohort 5 of Phase 1b Trial Company Intends to Initiate a Sixth Cohort and Transition Ongo
Fractionated Dosing Improves Tolerability and Safety of Cellectar's CLR 131 in R/R Multiple Myeloma Patients Positive Results from Cohort 5 of Company Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose MADISON, Wis. (August 20, 201
Read more →CLRBCellectar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma MADISON, Wis. (
Cellectar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma MADISON, Wis. (August 13, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati
Read more →CLRBCellectar Reports 2018 Second Quarter Financial Results and Provides Business Update MADISON, Wis. (
Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update MADISON, Wis. (August 10, 2018) - Cellectar Biosciences (Nasdaq: CLRB)("Cellectar or "the Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and comme
Read more →CLRBCellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate MADISON, Wis. and Courbevoie, France (
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate MADISON, Wis. and Courbevoie, France (August 1, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc
Read more →CLRBCellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option MADISON, Wis. (
Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option MADISON, Wis. (July 31, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, developm
Read more →CLRBCellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering MADISON, Wis. (
Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering MADISON, Wis. (July 27, 2018) - Cellectar Biosciences (Nasdaq: CLRB) ("Cellectar" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery, development and comm
Read more →CLRBCellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients 33% Overall Response Rate Observed in DLBCL Patient Cohort MADISON, Wis. (
Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients 33% Overall Response Rate Observed in DLBCL Patient Cohort MADISON, Wis. (July 18, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focus
Read more →CLRBCellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study MADISON, Wis. (
Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study MADISON, Wis. (July 17, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, develop
Read more →CLRBCellectar Announces 1-for-10 Reverse Stock Split Madison, Wis. (
Cellectar Announces 1-for-10 Reverse Madison, Wis. (July 13, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces a 1-for-10 rever
Read more →CLRBCellectar Announces 1-for-10 Reverse Stock Split
MADISON, Wis., July 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces a 1-for-10 reverse split of its common s
Read more →CLRBCellectar's CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing's Sarcoma MADISON, Wis. (
Cellectar's CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing's Sarcoma MADISON, Wis. (July 9, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for t
Read more →CLRBCellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial Response rate in cohort exceeded pre-specified value Madison, Wis. (
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial Response rate in cohort exceeded pre-specified Madison, Wis. (June 28, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the d
Read more →CLRBCellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131 MADISON, Wis. (
Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131 MADISON, Wis. (June 7, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati
Read more →CLRBFDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Rhabdomyosarcoma MADISON, Wis. (
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Rhabdomyosarcoma MADISON, Wis. (June 6, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and comme
Read more →CLRBCellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results
Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results MADISON, Wis., May 11, 2018 (GLOBAL NEWSWIRE) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization
Read more →CLRBCellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma MADISON, Wis. (
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma MADISON, Wis. (May 9, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatmen
Read more →CLRBCellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma MADISON, Wis. (
Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma MADISON, Wis. (May 2, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the
Read more →CLRBCellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma MADISON, Wis. (
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma MADISON, Wis. (April 17, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discover
Read more →CLRBPreclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar's CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting MADISON, Wis. (
Preclinical Data Highlighting Uptake Anti-Tumor Effects of Cellectar's CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting MADISON, Wis. (April 16, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery,
Read more →CLRBCellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer MADISON, Wis. (
Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer MADISON, Wis. (April 4, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments
Read more →CLRBCellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma MADISON, Wis. (
Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma MADISON, Wis. (April 3, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer
Read more →CLRBCellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
MADISON, Wis., March 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the U.S. Patent and Trademark Offi
Read more →CLRBC ellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles Covers composition of matter and method of use for proprietary PDCs in combination with anti-cancer agents MADISON,
Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles of matter and method of use for proprietary PDCs in combination with anti-cancer agents MADISON, Wis. (March 27, 2018) - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage bi
Read more →CLRBCellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on
Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018 MADISON, Wis. (March 19, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercializat
Read more →CLRBCellectar Reports 2017 Financial Results and Provides a Corporate Update Conference call to be held tomorrow at 8:30 a.m. Eastern time
Cellectar Reports 2017 Financial Results and Provides a Corporate Update Conference call to be held tomorrow at 8:30 a.m. Eastern time MADISON, Wis., March 21, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discov
Read more →CLRBCellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018
MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that management will host a teleconf
Read more →CLRBCellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma MADISON, Wis. (
Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma MADISON, Wis. (March 19, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for
Read more →CLRBCellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131 MADISON, Wis. (
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131 MADISON, Wis. (March 15, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs
Read more →CLRBPhase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12 th World Congress of the World Federation of Nuclear Medicine and Biology MADISON, Wis. (
1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology MADISON, Wis. (March 6, 2018) - Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutic
Read more →CLRBCellectar Biosciences to Present at Upcoming March Conferences Madison, Wis.
Cellectar Biosciences to Present at Upcoming Madison, Wis., March 5, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces
Read more →CLRBCellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference Madison, Wis.
Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference Madison, Wis., February 8, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the tre
Read more →CLRBCellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Madison, Wis.
Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Wis., February 7, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the trea
Read more →CLRBCellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers Madison, Wis.
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers Madison, Wis., January 29, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercializatio
Read more →CLRBCellectar Biosciences to Participate at Noble Capital Markets' Fourteenth Annual Investor Conference
Cellectar Biosciences to Participate at Noble Capital Markets' Fourteenth Annual Investor Conference MADISON, Wis., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and
Read more →CLRBCellectar Biosciences to Participate at Biotech Showcase 2018 Madison, Wis.
Cellectar Biosciences to Participate at Biotech Showcase 2018 Madison, Wis., January 4, 2018 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of canc
Read more →CLRBCellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers Madison, Wis.
Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers Madison, Wis., December 14, 2017 - Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatme
Read more →CLRBCellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131 Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit Madison, Wis.
Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131 myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit Madison, Wis., December 6, 2017 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmace
Read more →CLRBCellectar Biosciences to Present at the 10 th Annual LD Micro Main Event Madison, Wisc., (
Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event Wisc., (November 20, 2017) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of canc
Read more →CLRBCellectar Biosciences to Present at the 10th Annual LD Micro Main Event
Madison, Wis., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will be presenting at the 10t
Read more →CLRBCellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance Madison, Wisc. (
Cellectar Biosciences Reports Third Quarter Financial and Corporate Performance Madison, Wisc. (November 09, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today reported financial results and co
Read more →CLRBCellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma Madison, Wisc. (
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma (November 7, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"),
Read more →CLRBCellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance
MADISON, Wis., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that management will host a teleconference and live webcast to report third quarter 2017 financi
Read more →CLRBNew Preclinical Data Suggest That Cellectar Biosciences' PDC Platform Provides Enhanced Outcomes in Combination with External Radiation Madison, Wisc. (
New Preclinical Data Suggest That Cellectar Biosciences' PDC Platform Provides Enhanced Outcomes in Combination with External Radiation Madison, Wisc. (October 30, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotec
Read more →CLRBCellectar Biosciences Introduces Multiple Dose Regimen In Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Madison, Wisc. (
Cellectar Biosciences Introduces Multiple Dose Regimen In Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Wisc. (October 24, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today anno
Read more →CLRBCellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors Madison, Wisc. (
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors Madison, Wisc. (October 17, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology compa
Read more →CLRBCellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering
MADISON, Wis., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announces the closing of its registered direct offering, priced at-the-market, of 1,954,388 shares of its c
Read more →CLRBCELLECTAR BIOSCIENCES ANNOUNCES $7.76 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
CELLECTAR BIOSCIENCES ANNOUNCES $7.76 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET October 10, 2017 / -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announced that it entered into secu
Read more →CLRBCellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates Madison, Wisc., Castres, France (
Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates Castres, France (October 10, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), togethe
Read more →CLRBCellectar Biosciences to Present at The MicroCap Conference Madison, Wis., (
Cellectar Biosciences to Present at The Wis., (September 29, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at The MicroCap C
Read more →CLRBl Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131 Madison, Wisc. (
Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR Wisc. (September 27, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), to
Read more →CLRBCellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131
MADISON, Wis., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that a patient treated with the company’s lead PDC™ compound, CLR 131 in the fourth cohort of it
Read more →CLRBCellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates Madison, Wisc. (
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates Madison, Wisc. (September 21, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "
Read more →CLRBCellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference Madison, Wis., (
Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference Wis., (September 20, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will pre
Read more →CLRBCellectar Biosciences Appoints Jarrod Longcor Chief Business Officer Madison, Wis., (
Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer Wis., (September 18, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company (the "company"), announced that effective today Jarrod Longcor, the company's senior vice p
Read more →CLRBCellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
MADISON, Wis., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that it will present and meet with investors at the 19th Annual Rodman and Renshaw Global Investment Conference
Read more →CLRBCellectar Biosciences to Present at the 19 th Annual Rodman and Renshaw Global Investment Conference Madison, Wis., (
Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference Madison, Wis., (September 6, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company (the "company"), today announced that it will present and meet
Read more →CLRBCellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window Madison, Wisc. (
Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window Madison, Wisc. (August 22, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company")
Read more →CLRBCellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance Madison, Wisc. (
Cellectar Biosciences Reports Second Financial and Corporate Performance Madison, Wisc. (August 14, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces financial results for the second
Read more →CLRBCellectar Biosciences' CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients Madison, Wisc. (
Cellectar Biosciences' CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients Wisc. (August 8, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today annou
Read more →CLRBCellectar Biosciences to Host Conference Call on
Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance Madison, Wisc. (August 3, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company
Read more →CLRBCellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance
MADISON, Wis., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that management will host a teleconference and live webcast to report second quarter 2017 financi
Read more →CLRBCellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors Madison, Wisc. (
Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors Madison, Wisc. (August 1, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces the
Read more →CLRBCellectar Biosciences to Present at the 2017 Marcum MicroCap Conference Madison, Wisc., (
Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference Wisc., (June 6, 2017) -- Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused biotechnology company, today announced that president and CEO Jim Caruso will be presenting at 2017 Marcum MicroCap Confer
Read more →CLRBCellectar Biosciences to Present at the LD Micro Invitational Conference Madison, Wisc., (
Cellectar Biosciences to Present at the LD Micro Invitational Conference Wisc., (May 30, 2017) -- Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, Ju
Read more →CLRBThree Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings Madison, Wisc. (
Three Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings Madison, Wisc. (May 18, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), (the "company"), an oncology-focused, clinical stage biotec
Read more →CLRBCellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance Madison, Wisc. (
Cellectar Biosciences Reports First Quarter Financial and Corporate Performance Madison, Wisc. (May 11, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces financial results for first
Read more →CLRBCellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance
MADISON, Wis., May 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that management will host a teleconference and live webcast to report first quarter 2017 financia
Read more →CLRBCellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
MADISON, Wis., April 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces preclinical data that demonstrate the utility of the company’s lead compound, CLR 131, and CLR
Read more →CLRBCellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers Madison, Wisc. (
Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers Madison, Wisc. (April 25, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today a
Read more →CLRBUPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Madison, Wis. (
UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Madison, Wis. (April 21, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused clinical stage biotechnology company, today announces i
Read more →CLRBCellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells Madison, Wisc. (
Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells Madison, Wisc. (April 18, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announ
Read more →CLRBCellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. “Ce
Read more →CLRBCellectar Biosciences Adds Industry Veterans, Douglas Swirsky and Frederick Driscoll, to Its Board of Directors Madison, Wis. (
Cellectar Biosciences Adds Industry Veterans, Frederick Driscoll, to Its Board of Directors Madison, Wis. (April 10, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J. Swir
Read more →CLRBAfter Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers Madison, Wis. (
After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers Madison, Wis. (March 30, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused clinical stage biotechnology company,
Read more →CLRBCellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC Madison, Wisc. (
Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC Madison, Wisc. (March 21, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announce
Read more →CLRBCellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 Madison, Wisc. (
Cellectar Biosciences Reports 2016 Company and Continued Progress in First Quarter 2017 Madison, Wisc. (March 15, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces financial results
Read more →CLRBNewly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences' Intellectual Property Portfolio Madison, Wisc. (
Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences' Intellectual Property Portfolio Madison, Wisc. (March 14, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology comp
Read more →CLRBCellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance Madison, Wisc. (
Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance Madison, Wisc. (March 9, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), (the "company"), an oncology-focused, clinical stage
Read more →CLRBExpanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement Madison, Wisc. (
Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement Madison, Wisc. (March 8, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotec
Read more →CLRBCellectar Biosciences to Present at 29 th Annual Roth Conference Madison, Wis. (
Cellectar Biosciences to Present at 29th Annual Roth Conference Madison, Wis. (March 6, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company, announces today that its president and CEO, Jim Caruso, will present at the
Read more →CLRBCellectar Biosciences to Present at 29th Annual Roth Conference
MADISON, Wis., March 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that its president and CEO, Jim Caruso, will present at the 29th Annual Roth Conference on Wednesday, March 15th
Read more →CLRBCellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months Madison, Wis. (
Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches Madison, Wis. (February 27, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused clinic
Read more →CLRBUpon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma 25mCi/m2 Dose Determined to Be Safe and Well-Tolerated Madison, Wis. (
Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma 25mCi/m2 Dose Determined to Be Safe and Wis. (February 22, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focuse
Read more →CLRBCellectar Biosciences to Present at the 2 nd Annual Disruptive Growth & Healthcare Conference NEW YORK, NY / ACCESSWIRE /
Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference YORK, NY / ACCESSWIRE / February 9, 2017 / Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company, announces today that it will be presenting a
Read more →CLRBCellectar Biosciences to Present at 2017 BIO CEO & Investor Conference Madison, Wis. (
Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference Madison, Wis. (February 7, 2017) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will presen
Read more →CLRBCellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform Nature Reviews Clinical Oncology Online Publication and Oral Presentation at Academic Surgical Congress Further
Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform Nature Reviews Clinical Oncology Online Publication and Oral Presentation at Academic Surgical Congress Further Demonstrate the Potential of Madison, Wisc, (January 3
Read more →CLRBCellectar Biosciences to Present at NobleCon13
MADISON, Wis., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at NobleCon13, Noble Capital Markets’ 13th Annual Investor C
Read more →CLRBCellectar Biosciences to Present at NobleCon13 Madison, Wis. (
Cellectar Biosciences to Present Madison, Wis. (January 26, 2017) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at NobleCon13, Noble Capital Markets'
Read more →CLRBCellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors MADISON, Wis., (
Cellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors MADISON, Wis., (January 24, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused clinical stage biotechnology company, today announces that
Read more →CLRBCellectar Biosciences to Present at the 9 th Annual Biotech Showcase Madison, Wis. (
Cellectar Biosciences to Present at the 9th Annual Biotech Showcase Madison, Wis. (January 5, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the
Read more →CLRBCellectar Biosciences to Present at the 9th Annual Biotech Showcase
MADISON, Wis., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the Biotech Showcase in San Francisco on January 11, 2017 at 1
Read more →CLRBCellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs MADISON, Wis., (
Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs MADISON, Wis., (December 20, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused clinical stage biotechnology company, today announces
Read more →CLRBCellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types MADISON, Wis., (
Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types MADISON, Wis., (December 14, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused clinical stage biotechnology compa
Read more →CLRBCellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035 MADISON, Wis., (
Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035 MADISON, Wis., (December 12, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused clinical sta
Read more →CLRBCellectar Biosciences Presents Poster at the 58 th Annual Meeting of the American Society of Hematology Madison, WI (
Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology Madison, WI (December 6, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announced that
Read more →CLRBCellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology
MADISON, Wis., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced that it presented a poster at the 58th Annual Meeting of the American Society of Hematology in Sa
Read more →CLRBCellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently
Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies WI (December 1, 2016) -- Cellectar Bi
Read more →CLRBCellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option Madison, WI (
Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option Madison, WI (November 29, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "company"), an oncology-focused, c
Read more →CLRBCellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production Madison, WI (
Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Madison, WI (November 28, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an
Read more →CLRBCellectar Biosciences Announces Pricing of $8,000,000 Public Offering
MADISON, Wis., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or the "company"), an oncology-focused, clinical stage biotechnology company, today announces the pricing of an underwritten public offering of shares of its common stock, or i
Read more →CLRBCellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors Madison, WI (
Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors Madison, WI (November 17, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused,
Read more →CLRBCellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal T
Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial Madison, WI (November 15, 2016) -- Cellectar Biosci
Read more →CLRBCellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results Madison, WI (
Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results Madison, WI (November 10, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces key a
Read more →CLRBCellectar Biosciences to Host Conference Call on November 11 to Report Third Quarter 2016 Financial Results and Corporate Performance Madison, WI (
Cellectar Biosciences to Host Conference Call on November 11 to Report Third Quarter 2016 Financial Results and Corporate Performance Madison, WI (November 7, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), (the "company"), an oncology-focused, clinical stage biotechnol
Read more →CLRBCellectar Biosciences Announces Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma and Other Hematologic Malignancies Company Accelerates Guidance for Initiation of Trial; Anticipates Preliminary Data
Cellectar Biosciences Announces Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma and Other Hematologic Malignancies Company Accelerates Guidance for Initiation of Trial; Anticipates Preliminary Data as Early as Second Half of 2017 Madison, WI (October 31,
Read more →CLRBCellectar Biosciences Announces Data on CLR 131 Accepted For Poster Presentation at the 58 th Annual American Society of Hematology Meeting & Exposition Madison, WI (
Cellectar Biosciences Announces Data on CLR 131 Accepted For Poster Presentation at the 58th Annual American Society of Hematology Meeting & Exposition Madison, WI (October 24, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused, clinical
Read more →CLRBCellectar Biosciences To Present at BIO Investor Forum
MADISON, Wis., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that Jarrod Longcor, senior vice president of corporate development and operations, will present
Read more →CLRBCellectar Biosciences To Present at SeeThru Equity and Dawson James Investor Conferences
MADISON, Wis., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will be presenting at the following two investor
Read more →CLRBCellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma Madison, WI (
Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma Madison, WI (October 6, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused clinical stage biotechno
Read more →CLRBCellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603 MADISON, Wis., (
Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603 Wis., (October 4, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the "company"), an oncology-focused clinical stage biotechnology company, today announces that the United States Patent and
Read more →CLRBCellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma Single Dose Safety and Activity Performance Data from Second Patient Cohort Triggers Dose Escalation and Initia
Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma Single Dose Safety and Activity Performance Data from Second Patient Cohort Triggers Dose Escalation and Initiation of Third Cohort Madison, WI (September 29, 2016) -
Read more →CLRBCellectar Biosciences To Present at OktoberINVESTfest
MADISON, Wis., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will present at the OktoberINVESTfest presented by Joseph Gunna
Read more →CLRBCellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference
MADISON, Wis., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will present at the Ladenburg Thalmann 2016 Healthcare Conferen
Read more →CLRBCellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant Madison, WI (
Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant (September 12, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("the company"), an oncology-focused biotechnology company, today announce
Read more →CLRBCellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference
MADISON, Wis., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused biotechnology company, today announces that Jim Caruso, CEO of Cellectar, will present at the 18th Annual Rodman & Renshaw Global Investment Conference
Read more →CLRBCellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Madison, WI (
Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results (August 11, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("the company"), an oncology-focused biotechnology company, today announces key accomplishments and its financia
Read more →CLRBCellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance
MADISON, Wis., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (“the company”), an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to report second quarter 2016 financial results foll
Read more →CLRBCellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study Company to Accelerate CLR 131 Research in Multiple Myeloma and Other Hematologic Malignancies
Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study Company to Accelerate CLR 131 Research in Multiple Myeloma and Other Hematologic Malignancies MADISON, Wis., August 3, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB
Read more →CLRBCellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations MADISON, Wis., July 20, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("the company"), an oncology-focused biotechnology company, today announces t
Read more →CLRBCellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer
Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer MADISON, Wis., June 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("the company"), an oncology-focused biotechnol
Read more →CLRBCellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel CLR 1602 Tumor Selectivity Shown to be Approximately 30 Time
Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel CLR 1602 Tumor Selectivity Shown to be Approximately 30 Times Greater than Paclitaxel Alone MADISON, Wis., June 15,
Read more →CLRBCellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform Patent Covers Targeted Delivery to Cancer and Cancer St
Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Targeted Delivery to Cancer and Cancer Stem Cells MADISON, Wis., May 31, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences
Read more →CLRBCellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel
MADISON, Wis., May 25, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the Company”), an oncology-focused biotechnology company, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,345,718 on May 24, 2016, which cov
Read more →CLRBCellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference
MADISON, Wis., May 24, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the 5th Annual SeeThru Equity Microcap Investor Conference on Tuesday, May 31, 2016 at
Read more →CLRBCellectar Biosciences to Present at the 2016 Marcum MicroCap Conference Madison, WI (
Cellectar Biosciences to Present at the 2016 Marcum MicroCap Conference (May 23, 2016) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the 2016 Marcum MicroCap Conference at th
Read more →CLRBCellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO Patent Further Supports the Company's Phospholipid Drug Conjugate (PDC) Platform and Provides I
Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO Patent Further Supports the Company's Phospholipid Drug Conjugate (PDC) Platform and Provides Intellectual Property Protection for Chemotherapeutic Drug
Read more →CLRBCellectar Biosciences Satisfies All Nasdaq Listing Criteria
Biosciences Satisfies All Nasdaq Listing Criteria MADISON, Wis., May 16, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or the "company"), an oncology-focused biotechnology company, announces today that on May 16, 2016, Nasdaq issued a determin
Read more →CLRBCellectar Biosciences Announces First Quarter 2016 Financial Results Madison, WI (
Biosciences Announces First Quarter 2016 Financial Results (May 12, 2016) - Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces its financial results for the first quarter of 2016. During the first quarter of 2016, the company
Read more →CLRBCellectar Biosciences to Host Conference Call on May 12, 2016 to Report First Quarter 2016 Financial Results and Provide a Corporate Performance Update
MADISON, Wis., May 04, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to report first quarter 2016 financial results, followed by a review o
Read more →CLRBCellectar Biosciences Announces Successful Completion of $8 Million Public Offering Madison, WI
Cellectar Biosciences Announces Successful Completion of $8 Million Public Offering Madison, WI, April 20, 2016 - Cellectar Biosciences, Inc. (NASDAQ: CLRB) today announces the closing of its underwritten public offering of approximately 1.87 million shares of its common sto
Read more →CLRBCellectar Biosciences Announces Pricing of $7,000,000 Public Offering
MADISON, Wis., April 15, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the “company”) today announced the pricing of an underwritten public offering of common stock, or pre-funded warrants in lieu thereof, at a price of $2.13 per share and ass
Read more →CLRBCellectar Biosciences Receives Positive NASDAQ Listing Determination
MADISON, Wis., April 07, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), an oncology-focused biotechnology company, announced today that on April 6, 2016, the NASDAQ Listing Qualifications Panel (the “panel”) issued a determinati
Read more →CLRBCellectar Biosciences Announces Year End 2015 Financial Results Madison, WI (
Cellectar Biosciences Announces Year End 2015 Financial Results (March 10, 2016) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces financial results for the year ending December 31, 2015. Management will host a teleconfer
Read more →CLRBCellectar Biosciences to Present at the 28th Annual Roth Capital Conference
MADISON, Wis., March 08, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the 28th Annual Roth Capital Conference at the Ritz-Carlton Resort in Laguna Niguel,
Read more →CLRBCellectar Biosciences to Host Conference Call on March 10 to Report Year End 2015 Financials, Corporate Performance and 2016 Objectives
MADISON, Wis., March 07, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to report year end 2015 financial results, followed by a review of c
Read more →CLRBCellectar Biosciences Announces 1-for-10 Reverse Stock Split MADISON, WI (
Biosciences Announces 1-for-10 Reverse Stock Split MADISON, WI (March 4, 2016) - Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, today announces a 1-for-10 reverse stock split of its common stock, effective at the close of business today.
Read more →CLRBCellectar Biosciences to Present at the 2016 Biotech Showcase Madison, WI (
Biosciences to Present at the 2016 Biotech Showcase (January 7, 2016) - Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the Biotech Showcase in San Francisco on January 12, 2016 at
Read more →CLRBCellectar Biosciences Announces Positive Data from Phase 1 Therapeutic Trial of CLR 131 in Multiple Myeloma Safety and Activity Data Reviewed from First Cohort of Patients; CLR 131 Performance Triggers Advancement into S
Cellectar Biosciences Announces Positive Data from Phase 1 Therapeutic Trial of CLR 131 in Multiple Myeloma Safety and Activity Data Reviewed from First Cohort of Patients; CLR 131 Performance Triggers Advancement into Second Cohort at Higher Dose (January 5, 2016) -- Cellect
Read more →CLRBCellectar Biosciences and Pierre Fabre Laboratories Announce Oncology Research Collaboration Collaboration to Advance use of Phospholipid Drug Conjugate (PDC) Platform for Targeted Delivery of a selection of Pierre Fabre
Biosciences and Pierre Fabre Laboratories Announce Oncology Research Collaboration to Advance use of Phospholipid Drug Conjugate (PDC) Platform for Targeted Delivery of a selection of Pierre Fabre Cytotoxics CASTRES, France, Dec. 16th, 2015 (GLOBE NEWSWIRE) -Pierre Fabre, the t
Read more →CLRBCellectar Biosciences to Provide Update on Phase 1 Multiple Myeloma Study
MADISON, Wis., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces it plans to provide performance data from the first cohort of patients enrolled in its orphan drug designated Phase 1 study of CLR
Read more →CLRBCellectar Biosciences Chief Scientific Officer Receives International Recognition for Pioneering Research
MADISON, Wis., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces that its chief scientific officer and company founder, Jamey Weichert, Ph.D., received the Harry Fisher award for excellence in c
Read more →CLRBCellectar Biosciences Announces Third Quarter Financial Results Madison, WI (
Cellectar Biosciences Announces Third Quarter Financial Results (November 12, 2015) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces financial results for the third quarter During the third quarter of 2015, the company r
Read more →CLRBCellectar Biosciences Converts Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles
MADISON, Wis., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the Company), an oncology-focused biotechnology company, today announces that it has converted its previously filed provisional patent application for Phospholipid-Ether Analogs as Cancer
Read more →CLRBCellectar Biosciences to Host Conference Call on November 12th to Discuss Third Quarter Financial Results and Provide Clinical Development Program Update
MADISON, Wis., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to discuss third quarter 2015 financial results and review the company
Read more →CLRBCellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update
MADISON, Wis., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today provides an update on its recently initiated Phospholipid Drug Conjugate (PDC) chemotherapeutic program, CLR CTX. PDCs are a new class of s
Read more →CLRBCellectar Biosciences to Present at the 2015 BIO Investor Forum
MADISON, Wis., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the BIO Investor Forum in San Francisco on October 20, 2015 at 1:30 PM PT. "The BIO I
Read more →CLRBCellectar Biosciences Closes on $3.3 Million Financing
MADISON, Wis., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) today announced the closing of its registered direct offering of 1,017,272 shares of its common stock and Series B pre-funded warrants to purchase 482,728 shares of common stock at a price o
Read more →CLRBCellectar Biosciences Awarded $2.3M National Cancer Institute Fast-Track SBIR Grant to Advance Phospholipid Drug Conjugate (PDC) Delivery Platform
MADISON, Wis., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical stage biopharmaceutical company developing phospholipid drug conjugates (PDCs) for cancer targeted delivery of diverse oncologic payloads for the treatment of cancer, announced t
Read more →CLRBCellectar Biosciences Announces Pricing of $3.3 Million Financing Madison, WI
Biosciences Announces Pricing of $3.3 Million Financing Madison, WI, September 28, 2015 (GLOBE NEWSWIRE) - Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar") today announced the pricing of a registered direct offering of 1,017,272 shares of its common stock and Series B p
Read more →CLRBCellectar Biosciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference
MADISON, Wis., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the Ladenburg Thalmann 2015 Healthcare Conference in New York City on September 29, 2
Read more →CLRBCellectar Biosciences to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
MADISON, Wis., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City on Sept
Read more →CLRBCellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics
MADISON, Wis., Aug. 21, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, recently introduced its Phospholipid ether-Drug Conjugate (PDC) platform for expanding the use of its proprietary small-molecule cancer targeting
Read more →CLRBCellectar Biosciences Announces 2 nd Quarter Financial Results Madison, WI (
Cellectar Biosciences Announces 2nd Quarter Financial Results 12, 2015) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), today announces financial results for the second quarter of 2015. During the second quarter of 2015, the company reported a net loss for of $2.3 million or (
Read more →CLRBCellectar Biosciences Announces 2nd Quarter Financial Results
MADISON, Wis., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), today announces financial results for the second quarter of 2015. During the second quarter of 2015, the company reported a net loss for of $2.3 million or ($0.30) per share versus a net
Read more →CLRBCellectar Biosciences to Host Conference Call on August 12th to Discuss Second Quarter Financial Results and Provide Update on Development Plans
MADISON, Wis., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), today announces that management will host a teleconference and live webcast to discuss second quarter 2015 financial results and review the company's development plans on Wednesday, August
Read more →CLRBCellectar Appoints Industry Veteran Jim Caruso President and Chief Executive Officer Dr. Simon Pedder to Retire Madison, WI (
Cellectar Appoints Industry Veteran Jim Caruso President and Chief Executive Officer Dr. Simon Pedder to Retire (June 16, 2015) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), today announces that James V. Caruso was appointed as president and chief executive officer yesterday,
Read more →CLRBCellectar Biosciences Announces CLR1502 Development Program to be Classified as Combination Product by U.S. Food and Drug Administration Cellectar to Re-submit Investigational Application as Combination Product Prior to
Biosciences Announces CLR1502 Development Program to be Classified as Combination Product by U.S. Food and Drug Administration to Re-submit Investigational Application as Combination Product Prior to Initiating Proof-of-Concept Trial of Tumor Margin Illumination Agent in Brea
Read more →CLRBCellectar Biosciences Announces Intent to Adjourn Annual Meeting Of Stockholders Meeting to be reconvened on
Biosciences Announces Intent to Adjourn Annual Meeting Of Stockholders to be reconvened on June 9, 2015 at 10:00 AM Central Time Directors Wishes to Provide Stockholders with Sufficient Time to Review Amendments to the Company's Annual Report MADISON, Wis., May 26, 2015, - Ce
Read more →CLRBCellectar Biosciences Reports First Quarter 2015 Financial Results and Provides Update on Clinical Programs
MADISON, Wis., May 21, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an update on its development programs and financial results f
Read more →CLRBCellectar Biosciences to Host Conference Call on May 21st to Discuss First Quarter 2015 Results and Provide Update on Development Programs
MADISON, Wis., May 20, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to
Read more →CLRBCellectar Biosciences Reschedules Release of First Quarter Financials and Quarterly Conference Call
MADISON, Wis., May 11, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that it is rescheduling the release of its first quarter financi
Read more →CLRBCellectar Biosciences to Host Conference Call on May 12th to Discuss First Quarter 2015 Results and Provide Update on Development Programs
MADISON, Wis., May 5, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to d
Read more →CLRBCellectar Biosciences Initiates Proof-of-Concept Trial of I-131-CLR1404 in Multiple Myeloma
Cellectar Biosciences Initiates Proof-of-Concept Trial of I-131-CLR1404 in Multiple Myeloma MADISON, Wis., April 15, 2015, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of
Read more →CLRBCellectar Biosciences Full-Year 2014 Financial Results and Recent Highlights Management to Host Conference Call and Webcast Today at 5:00
Cellectar Biosciences Full-Year 2014 Financial Results and Recent Highlights Management to Host Conference Call and Webcast Today at 5:00 PM EDT MADISON, Wis., March 24, 2015, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing
Read more →CLRBCellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress
Cellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress MADISON, Wis., March 17, 2015, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company
Read more →CLRBCellectar Biosciences to Present at 27th Annual Roth Conference
MADISON, Wis., March 4, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced that Dr. Jamey Weichert, Chief Scientific Officer and fou
Read more →CLRBCellectar Biosciences to Present at 27 th Annual Roth Conference
Cellectar Biosciences to Present at 27th Annual Roth Conference MADISON, Wis., March 4, 2015, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced that
Read more →CLRBCellectar Biosciences to Present at the 17th Annual BIO CEO & Investor Conference 2015
MADISON, Wis., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced that Dr. Simon Pedder, president and CEO, will present at
Read more →CLRBPeer-Reviewed Glioma Surgery Study with Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery
Peer-Reviewed Glioma Surgery Study with Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery MADISON, Wis., January 22, 2015, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innova
Read more →CLRBCellectar Biosciences to Present at the Biotech Showcase 2015 Conference
Cellectar Biosciences to Present at the Biotech Showcase 2015 Conference MADISON, Wis., January 9, 2015, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced
Read more →CLRBCellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma
Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma MADISON, Wis., December 4, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection a
Read more →CLRBCellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development
Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development MADISON, Wis., November 25, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), announced the appointment of Cameron Szakacs, Ph.D., as vice president of clinical development. Dr. Szakac
Read more →CLRBCellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights Management to Host Conference Call and Webcast at 5:00
Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights to Host Conference Call and Webcast at 5:00 PM EST MADISON, Wis., November 11, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative ag
Read more →CLRBCellectar Biosciences to Host Conference Call on November 11th to Discuss Third Quarter 2014 Results and Provide Quarterly Update on Development Progress
MADISON, Wis., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to
Read more →CLRBCellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer
Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer MADISON, Wis., October 15, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), announced that an article reporting the effica
Read more →CLRBCellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September
Rodman & Renshaw 16th Annual Global Investment Conference on September 9, 2014 Aegis Capital 2014 Healthcare and Technology Conference on September 11, 2014 Webcasts Available Through Cellectar Corporate Website MADISON, Wis., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosci
Read more →CLRBCellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma MADISON, Wis., September 4, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), announced today that the U.S. Food &
Read more →CLRBCellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option
Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option MADISON, Wis., August 20, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection
Read more →CLRBCellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights
MADISON, Wis., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial result
Read more →CLRBCellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress
MADISON, Wis., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second
Read more →CLRBCellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market
Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market MADISON, Wis., August 14, 2014, - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and tre
Read more →CLRBCellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple MADISON, Wis., August 11, 2014, - Cellectar Biosciences, Inc. (OTCQX: CLRB), announced that it has submitted an Investigational New Drug (IND)
Read more →CLRBBiosciences Announces 1-for-20 Reverse Stock Split and Reduction
Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common Stock MADISON, Wis., June 13, 2014, - Cellectar Biosciences, Inc. (OTCQX: CLRB), announced a 1-for-20 reverse stock split of its common stock, effective at the close of business to
Read more →CLRBCellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common Stock
MADISON, Wis., June 13, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), announced a 1-for-20 reverse stock split of its common stock, effective at the close of business today, as a first step in a planned listing of its common stock on the NASDAQ Capital Market
Read more →CLRBArticle entitled "Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy" from Science Translational Medicine
Article entitled "Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy" from Science Translational Medicine, June 11, 2014, vol. 6 issue 240. Reprinted with permission from AAAS. Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007646 Alkylphosphocholine Anal
Read more →CLRBBackground Materials/Methods Results Conclusions Funding source: Funding provided by Cellectar Biosciences, Inc. A phase 1 study of phospholipid ether [ 131 I] - CLR1404 in patients with advanced solid tumors. S. J. Lubn
Background Materials/Methods Results Conclusions Funding source: Funding provided by Cellectar Biosciences, Inc. A phase 1 study of phospholipid ether [ 131 I] - CLR1404 in patients with advanced solid tumors. S. J. Lubner 1 , J. A. Mullvain 1 , L. T. Hall 1 , M. Pishvaian 2 , J.
Read more →CLRBCellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting
MADISON, Wis., May 30, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that presentations highlighting the company's cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs) and its radiother
Read more →CLRBCellectar Biosciences Appoints Chad J. Kolean Chief Financial Officer
Biosciences Appoints Chad J. Kolean Chief Financial Officer MADISON, Wis., May 29, 2014, - Cellectar Biosciences, Inc. (OTCQX: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced the appointm
Read more →CLRBCellectar Biosciences Reports First Quarter 2014 Financial Results and Recent Highlights
MADISON, Wis., May 14, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results
Read more →CLRBCellectar Biosciences to Host Conference Call on May 14th to Discuss First Quarter 2014 Results and Provide Quarterly Update on Development Progress
MADISON, Wis., May 12, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss first qu
Read more →CLRBCellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration Company Expects to Complete Ongoing Multi-Center Phase II I
Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration Company Expects to Complete Ongoing Multi-Center Phase II Imaging Trial of I-124-CLR1404 in Patients with Glioblasto
Read more →CLRBDr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences MADISON, Wis., April 2, 2014, - Cellectar Biosciences, Inc. (OTCQX: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced
Read more →CLRBCellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights Management to Host Conference Call and Webcast at 5:00
Biosciences Full-Year 2013 Financial Results and Recent Highlights to Host Conference Call and Webcast at 5:00 PM EDT Wis., March 25, 2014, - Cellectar Biosciences, Inc. (OTCQX: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection an
Read more →CLRBCellectar Biosciences March 2014 Safe Harbor Statement This slide presentation contains forward - looking statements . Such statements are valid only as of today, and we disclaim any obligation to update this information
Cellectar Biosciences March 2014 Safe Harbor Statement This slide presentation contains forward - looking statements . Such statements are valid only as of today, and we disclaim any obligation to update this information . These statements are only estimates and predictions and
Read more →CLRBCellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
MADISON, Wis., March 19, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full y
Read more →CLRBCellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Cellectar Expects Results from this 36-Patient, Multi-Center Imaging Trial by Year-En
Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Cellectar Expects Results from this 36-Patient, Multi-Center Imaging Trial by Year-End 2014 MADISON, Wis., March 04, 2014, - Cellectar Biosciences, Inc
Read more →CLRBNovelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc. Stock to be Quoted Under Ticker Symbol CLRB Beginning
Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc. Stock to be Quoted Under Ticker Symbol CLRB Beginning February 12, 2014 MADISON, Wis., February 11, 2014, - Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents
Read more →CLRBNovelos Therapeutics Announces Definitive Agreements to Raise $4.0 million in Private Placement of Convertible Debentures and Warrants Proceeds Enable Initiation of Phase II Trial of 124 I-CLR1404 in Glioma in First Quar
Therapeutics Announces Definitive Agreements to Raise $4.0 million in Private Placement of Convertible Debentures and Warrants Proceeds Enable Initiation of Phase II Trial of 124I-CLR1404 in Glioma in First Quarter 2014 MADISON, Wis. (February 06, 2014) - Novelos Therapeutics
Read more →CLRBDeveloping Novel Drugs for the Diagnosis and Treatment of Cancer Novelos Therapeutics, Inc. (OTCQX: NVLT), November 2013 Safe Harbor Statement FIND . TREAT . FOLLOW . 2 This slide presentation contains forward - looking
Developing Novel Drugs for the Diagnosis and Treatment of Cancer Novelos Therapeutics, Inc. (OTCQX: NVLT), November 2013 Safe Harbor Statement FIND . TREAT . FOLLOW . 2 This slide presentation contains forward - looking statements . Such statements are valid only as of today, an
Read more →CLRBNovelos Appoints Industry Veteran to Lead Strategic Realignment MADISON, Wisc. (
Industry Veteran to Lead Strategic Realignment MADISON, Wisc. (October 9, 2013) - Novelos Therapeutics, Inc. (OTCQX: NVLT) announced that the Board of Directors, on October 4, 2013, appointed Dr. Simon Pedder as Acting Chief Executive Officer and elected him a Director, replac
Read more →CLRBNOVELOS THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION - - - MADISON, Wisc. (
NOVELOS THERAPEUTICS ANNOUNCES LEADERSHIP MADISON, Wisc. (July 29, 2013) - Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, the company's President and CEO an
Read more →CLRBNovelos Therapeutics, Inc. ( OTCQX : NVLT) Developing Novel Drugs for the Treatment and Diagnosis of Cancer
Novelos Therapeutics, Inc. ( OTCQX : NVLT) Developing Novel Drugs for the Treatment and Diagnosis of Cancer May 23, 2013 FIND . TREAT. FOLLOW . 2 DISCLAIMER This slide presentation contains forward - looking statements . Such statements are valid only as of today, and we disclai
Read more →CLRBNOVELOS THERAPEUTICS PROVIDES PRODUCT PIPELINE UPDATE - - - To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 Evaluating I-131-CLR1404 (HOT) Potential Phase 2 Indications an
NOVELOS THERAPEUTICS PROVIDES PRODUCT To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 Evaluating I-131-CLR1404 (HOT) Potential Phase 2 Indications and Trial Designs To File CLR1502 (GLOW2) IND for Intraoperative Tumor Margin Illumination b
Read more →CLRBNOVELOS THERAPEUTICS CLOSES $5.5 MILLION
NOVELOS THERAPEUTICS CLOSES $5.5 MILLION MADISON, Wisc. (February 21, 2013) - Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a public offering of 11,000,000 uni
Read more →CLRBNOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING MADISON, Wisc. (
NOVELOS THERAPEUTICS PRICES $5.5 MILLION Wisc. (February 13, 2013) - Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at $0.5
Read more →CLRBNOVELOS THERAPEUTICS ANNOUNCES POSITIVE INITIAL IMAGING RESULTS IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER - - - Expects Final Ima
NOVELOS THERAPEUTICS ANNOUNCES POSITIVE INITIAL IMAGING RESULTS IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER Expects Final Imaging Results in the First Quarter 2013 WI, June 19, 2012 - Novelos Therapeutics, Inc. (OTCQ
Read more →CLRBNOVELOS THERAPEUTICS CLOSES $5.4 MILLION PUBLIC OFFERING - - - Announces Dismissal with Prejudice of Putative Federal Securities Class Action Lawsuit MADISON, WI
NOVELOS THERAPEUTICS CLOSES $5.4 MILLION Announces Dismissal with Prejudice of Putative Federal Securities Class Action Lawsuit MADISON, WI, June 14, 2012 - Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnos
Read more →CLRBNOVELOS THERAPEUTICS PRICES $5.4
NOVELOS THERAPEUTICS PRICES $5.4 MILLION WI, June 8, 2012 - Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 5,420,800 units at $1.00 per unit
Read more →CLRBNOVELOS THERAPEUTICS CLOSES $6
NOVELOS THERAPEUTICS CLOSES $6 MILLION PUBLIC OFFERING MADISON, WI, December 7, 2011 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the closing of an underwritten public offering
Read more →CLRBNOVELOS THERAPEUTICS PRICES $5.9
NOVELOS THERAPEUTICS PRICES $5.9 MILLION PUBLIC OFFERING MADISON, WI, December 1, 2011 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offerin
Read more →CLRBPLACEMENT
PLACEMENT AGENCY AGREEMENT Rodman & Renshaw, LLC 1251 Avenue of the Americas New York, New York 10020 Novelos Therapeutics, Inc., a Delaware corporation (the "Company"), hereby confirms its agreement with Rodman & Renshaw, LLC, a Delaware limited liability company (the "Place
Read more →Competitive Position
How CLRB ranks across every disease it competes inCompetitive Position is a premium feature
See how CLRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial